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1 Introduction 
1.1 Idiopathic pulmonary fibrosis (IPF) 
1.1.1 Classification 
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. It leads to a 
destruction of the lungs’ architecture by accumulation of scar tissue and causes 
respiratory failure 
1
. By classification, IPF belongs to the diffuse parenchymal lung 
diseases (DPLDs), more precisely to the idiopathic interstitial pneumonias (IIPs), a 
subset of the DLPDs with unknown etiology 
2
. Seven IIP entities were specified in a 
Consensus Classification by the American Thoracic Society and the European 
Respiratory society in 2002 
2
: idiopathic pulmonary fibrosis (IPF), nonspecific 
interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), acute 
interstitial pneumonia (AIP), respiratory bronchiolitis-associated interstitial lung disease 
(RB-ILD), desquamative interstitial pneumonia (DIP) and lymphocytic interstitial 
pneumonia (LIP). A scheme of the DPLDs is depicted in figure 1. 
 
 
 
Figure 1.  Diffuse parenchymal lung diseases 
2
 
The scheme depicts the group of diffuse parenchymal lung diseases (DPLDs), including the 
idiopathic interstitial pneumonias (IIPs). The IIPs can be divided into idiopathic pulmonary 
fibrosis (IPF) and IIPs other than IPF 
2
. Reprinted with permission of the American Thoracic 
Society. Copyright © 2013 American Thoracic Society. 
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All IIPs affect the lung interstitium and cause respiratory deterioration 
2
. However, IPF 
is the most frequent entity, as it is responsible for more than half of all cases 
13,81
. It fur-
thermore has a worse prognosis than other IIPs 
2,13
. For precise diagnostic classification 
and assessment of therapeutic options, these several entities have to be distinguished by 
specific criteria on high-resolution computed tomography (HRCT) or lung biopsy 
2
. 
 
1.1.2 Diagnostic criteria 
The new, evidence-based guidelines implemented by cooperation of the American Tho-
racic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory 
Society (JRS) and the Latin American Thoracic Association (ALAT) in 2011 define IPF 
as ‘a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown 
cause, occurring primarily in older adults, limited to the lungs, and associated with the 
histopathologic and / or radiologic pattern of UIP (usual interstitial pneumonia)’ 133. The 
revised diagnostic criteria for IPF demand the following 
133
: 
 
1. The exclusion of other known causes of interstitial lung disease, such as domestic 
and occupational environmental exposures, connective tissue disease and drug 
toxicity. 
2. The presence of a UIP pattern on HRCT in patients not subjected to surgical lung 
biopsy. 
3. Specific combinations of HRCT and surgical lung biopsy pattern in patients 
subjected to surgical lung biopsy 
133
. 
 
It is emphasized that a multidisciplinary approach involving pulmonologists, radiolo-
gists and pathologists with experience in the field of interstitial lung diseases improves 
the validity of the diagnosis 
133
. 
 
1.1.3 Clinical, histological and radiological characteristics 
IPF can be found worldwide. The age of occurrence is usually 50 years or older, with a 
typical manifestation in the sixth and seventh decade of life 
133
. Its incidence is estimat-
ed by 7 to 11 cases per 100000 persons a year, is higher in male than in female gender 
and increases with age 
36,73,161
. There are cases of familial IPF that are considered to 
represent less than 4 % of all IPF cases 67,107 . These cases show similar characteristics 
and a similar outcome as the more frequent sporadic cases 
14,93
. 
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Clinical symptoms of IPF patients include dyspnea, nonproductive coughing, digital 
clubbing and “Velcro”-type inspiratory crackling at lung auscultation 2,133. The respira-
tory function is impaired, especially under exertion, and pulmonary function testing 
reveals a restrictive pattern with deterioration of gas exchange. Pulmonary hypertension 
and cor pulmonale can develop in the course of the disease 
1
. 
The histopathological equivalent of IPF is the usual interstitial pneumonia (UIP) pat-
tern, which summarizes alterations of the lungs’ architecture 2. Prominent findings are 
an enhanced deposition of extracellular matrix components with formation of dense 
scars, honeycomb cysts (dilated bronchioles), an impaired alveolar epithelium and a 
mild interstitial inflammation 
2,75,133,167
. The histological hallmark lesions of IPF are 
fibroblast foci, aggregates of activated myofibroblasts and fibroblasts 
36
 typically found 
in close relation to the alveolar septa 
75,167
 (figure 2A). In some studies their quantity 
has been associated with a worse prognosis 
41,84,120
, but deviating observations have 
been reported as well 
43
. The pathological changes of lung architecture are predominant-
ly located in the peripheral, subpleural and paraseptal parts of the lung tissue, arranged 
in heterogeneous patterns 
133
. According to this, severely altered regions can be found 
next to areas with normal structural appearance 
133
. 
Typical findings on HRCT are a bilateral, mainly basal and subpleural localized reticu-
lar pattern and structural alterations as honeycomb cysts, bronchiectasis and focal 
ground glass opacities 
2,133
 (figure 2B). 
 
 A.           B. 
 
Figure 2.  Histological and radiological characteristics of IPF. 
(A) Histological alterations of the lung tissue in IPF, the arrows indicate a fibroblast focus 
75
. 
(B) An IPF lung on HRCT 
2
. Reprinted with permission of the American Thoracic Society. 
Copyright © 2013 American Thoracic Society. 
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1.1.4 Pathogenesis 
Genetic predisposition as well as the influence of environmental factors have been in-
vestigated for identifying possible causes of IPF 
14,36,57,133
. Thus, cigarette smoking has 
been associated with an increased risk to develop IPF 
9,133
 and several other potential 
risk factors such as a shortened telomere length, medication, chronic aspiration or viral 
infections are still under discussion 
3,14,24,36,83,133
. However, there is no specific risk fac-
tor that can be considered as sole trigger for disease initiation and IPF still has to be 
classified as “idiopathic” 14,36. 
The mechanisms underlying disease initiation and progression on the cellular and mo-
lecular level, leading to extensive fibrosis and destruction of the lungs’ architecture, are 
not fully understood either 
11,157
. More recent hypotheses about IPF pathophysiology 
have questioned its former understanding as a result of chronic inflammation 
47,56,142
. 
These theories are supported by findings that inflammation in IPF lung tissues is not 
very prominent 
75,142
 and patients do not adequately respond to anti-inflammatory treat-
ment 
36,56
. It has rather been suggested that repetitive epithelial injuries in combination 
with a malfunction of repair processes, whether an inflammatory response may be in-
cluded or not, are the key mechanisms of IPF pathogenesis 
22,142
. An impaired epithelial 
function with disturbed re-epithelialization and hyperplasia of alveolar epithelial cells as 
well as an enhanced fibroblast activation are components of this process 
142,160
. Fibro-
blast foci are seen as regions of an ongoing fibroblast / myofibroblast activation with 
the myofibroblast cell-type mainly responsible for extensive accumulation of extracellu-
lar matrix and therefore representing a key component of disease progres-
sion 
75,128,141,171
. The origin of activated myofibroblasts is still under discussion. Hy-
potheses include the proliferation and activation of resident pulmonary fibroblasts, the 
recruitment of circulating progenitor cells that originate from the bone marrow and epi-
thelial-mesenchymal transition (EMT), a process in which alveolar epithelial type II 
(ATII) cells can shift to a mesenchymal, fibroblast-like phenotype 
39,141,157
. As fibroblast 
foci are primarily found in areas of impaired alveolar epithelium 
75,167
, epithelial-
mesenchymal interactions via growth factors and cytokines are assumed to drive the 
fibrosing process 
69,143
. However, despite the large number of investigations on underly-
ing mechanisms and mediators, the exact nature of IPF pathogenesis has not been fully 
elucidated yet 
11,42,123,157
. 
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1.1.5 Course of disease and treatment 
With a median survival between 2.5 and 3.5 years after diagnosis, the prognosis of IPF 
is poor 
2,36
. It is a progressive disease that leads to the destruction of the lungs’ architec-
ture and causes respiratory failure 
1,112
. Yet, the course of disease for an individual pa-
tient seems to be variable, with periods that appear fairly stable and periods of acute 
exacerbations that have a poor outcome 
28,81,83,108,133
. Acute or subacute deterioration of 
respiratory function as well as respiratory infections or right heart failure were identi-
fied as disease related causes of death 
1,108
. 
To date, a multitude of treatment studies for IPF have been initiated, including 
immunomodulatory, immunosuppressant, antioxidant, antifibrotic, vascular resistance 
modulatory and anticoagulatory approaches 
36,38,48,58,124
. However, in almost all cases 
they either did not show a prominent effect on IPF progression or even turned out to be 
harmful, their therapeutic value has to be considered as unclear or they are still in the 
phase of clinical trials 
38,45,58,112,168
. Therefore, for the majority of IPF patients, none of 
these treatment strategies has been recommended by the current ATS/ERS/JRS/ALAT 
guidelines 
133
. There are some pharmacological treatments that may be considered as a 
reasonable choice for a minority of IPF patients, including pirfenidone 
133
. Pirfenidone 
possesses antifibrotic, anti-inflammatory and antioxidant properties and can antagonize 
cellular mechanisms induced by transforming growth factor-β (TGF-β) 3,133. It has re-
cently been approved in Europe, India, Japan and China for the treatment of patients 
with mild to moderate IPF 
64
. In a Cochrane review assessing several clinical trials, 
pirfenidone seemed to improve the progression-free survival of IPF patients by about 
30 % 64,155. Reliable data on the overall survival of patients treated with pirfenidone are 
still missing 
64,155
. 
Lung transplantation is a therapeutical option with a proven and considerable benefit on 
survival of IPF patients 
45,124,133,168
. However, access to donor organs is restricted and a 
comparatively high age or associated comorbidities of IPF patients represent limiting 
factors for a successful referral to transplantation 
64,172
. Further recommendations in-
clude corticosteroid therapy in the event of acute exacerbations, the treatment of coex-
isting gastroesophageal reflux and long-term oxygen therapy 
133
. 
Since the effects of present pharmaceutical treatments are limited, it emphasizes the 
need for a better understanding of the pathomechanisms that underlie disease initiation 
and progression. Hence, many recent studies have focused on molecular processes that 
6 
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might be involved. Some proteins and signaling pathways have obtained particular at-
tention, including WNT signaling 
24,141
. 
 
1.2 WNT signaling 
1.2.1 WNT proteins 
WNTs are secreted glycoproteins, related by their amino acid sequences 
101,114
. Their 
name derived from a combination of the gene names wingless and int-1, which were 
described independently, but were later identified to be homologous 
135
. In mammals, 
19 different WNT genes have been detected 
101,114
. The signaling cascades of WNT pro-
teins are of importance during embryogenesis and in the homeostasis of adult tissues 
101
. 
Stem cell behavior, proliferation and differentiation processes as well as cell polarity are 
influenced by WNT 
114,126
. Alterations of its signaling cascade were detected in various 
diseases and especially the role of WNT in cancer has been closely investigated 
50,114
. 
Colorectal cancer, hepatocellular carcinoma and lung cancer are only some of the neo-
plasms that have been associated with mutations of WNT pathway components 
27,50
. 
 
1.2.2 WNT signal transduction 
WNT signaling is a complex process that involves several pathways with a number of 
ligands and receptors. There are different and so far incompletely understood crosslinks 
between the single participants and other transmitter cascades, as well as an extensive 
regulatory network 
54,102,111,165
. 
At least three pathways of WNT signaling have been described 
27,79,87
: 
 WNT/β-catenin (canonical) pathway 
 WNT/JNK planar cell polarity pathway 
 WNT/Ca2+ pathway 
Up to now, although several details of the molecular mechanisms still have to be clari-
fied, the canonical pathway is the best studied WNT signaling cascade 
5,7,27
. 
 
1.2.2.1 WNT/β-catenin signaling pathway 
β-catenin, a protein also involved in cell adhesion, is the key molecule of signal trans-
duction via the canonical pathway 
16
. Under unstimulated conditions (figure 3A), cyto-
plasmic β-catenin is continuously phosphorylated by a complex consisting of glycogen 
synthase kinase 3β (GSK3β), casein kinase 1 (CK1), adenomatous polyposis coli (APC) 
and Axin 
5,102
. Phosphorylated β-catenin is ubiquitinated and degraded by the pro-
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teasome, with the result that cytoplasmic β-catenin levels are low 101,114. WNT stimula-
tion leads to changes in the β-catenin metabolism (figure 3B). For initiation of signal 
transduction, WNT has to interact with two different kinds of cell surface receptors. On 
the one hand, it binds to Frizzled proteins (FZD1-10) 
125
, a family of seven-
transmembrane-spanning WNT receptors. On the other hand, it has to bind to single-
pass transmembranous WNT coreceptors of the low density lipoprotein receptor-related 
protein family (LRP5 and LRP6) 
29,101,114
. Following this interaction, LRP is phosphory-
lated by GSK-3β and casein kinase 1γ (CK1γ) at its intracytoplasmic portion 27,54,180. 
Dishevelled (DSH) is phosphorylated and Axin is recruited, which directly binds to 
LRP 
18,54,106
. The exact molecular mechanisms still have to be elucidated, but as a result 
of DSH phosphorylation and of the interaction of LRP and Axin, the GSK3β/APC/Axin 
complex is inhibited and therefore β-catenin phosphorylation and its degradation are 
prevented 
18,54
. β-catenin accumulates in the cytoplasm and translocates to the nucleus, 
where it interacts with members of the T cell-specific transcription factor / lymphoid 
enhancer-binding factor (TCF/LEF) protein family, thereby modifying target gene ex-
pression 
18,54,114
. 
 
    A.            B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  WNT/β-catenin signaling pathway. 
(A) In the absence of WNT, β-catenin is degraded. (B) Changes induced by WNT stimulation. 
Inspired by an illustration by Michael D. Gordon and Roel Nusse 
54
. 
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1.2.3 WNT in the lung – embryogenesis and diseases of the adult 
In mice, WNT signaling was found essential for several basic processes of lung devel-
opment, including foregut specification 
55
, embryonic branching morphogenesis and 
distal airway formation 
95,117
. A significant impact of WNT proteins on proper devel-
opment and differentiation of the epithelial, mesenchymal, and vascular compartment of 
the lung has been stated 
95,116,117,152
. 
Lung cancer has been related to alterations in WNT signaling, particularly non-small-
cell lung carcinomas (NSCLCs) 
87,109,166
. In detail, an overexpression of the proteins 
WNT1 
61
 and WNT2 
177
 was reported for NSCLC tissues and WNT1 overexpression 
has been associated with NSCLC proliferation 
71
. An inhibition of these mediators was 
linked with apoptosis of cancer cells 
61,177
. Furthermore, non-malignant lung diseases 
have been examined for an involvement of WNT signaling, such as pulmonary arterial 
hypertension and IPF 
87
. 
 
1.2.3.1 WNT in IPF 
By now there has been good evidence for an abnormal activation of the WNT/β-catenin 
pathway in IPF. An increase in nuclear β-catenin accumulation has been reported for 
bronchiolar lesions, atypical (cuboidal/hyperplastic) alveolar epithelial type II (ATII) 
cells and fibroblasts in the lung tissue of IPF patients, indicating an increase in active 
WNT/β-catenin signaling 26. While WNT/β-catenin pathway activation in hyperplastic 
type II pneumocytes could also be demonstrated for other lung diseases involving al-
veolar damage and regeneration, the aberrant activation of WNT/β-catenin signaling in 
bronchiolar proliferative lesions and fibroblast foci was specific for IPF when compared 
to donor lungs and other interstitial lung diseases 
26
. Further WNT/β-catenin pathway 
components were predominantly found in the bronchial and alveolar epithelium and 
some exhibited a significantly increased mRNA expression in lung tissue homogenates 
as well as in isolated ATII cells of IPF patients 
86
. The presumed enhancement of path-
way activation was supported by an increase in protein levels of phosphorylated 
GSK3β, phosphorylated LRP6 and β-catenin in IPF lung tissue homogenates 86. Fur-
thermore, an elevated expression of WNT/β-catenin target genes and their encoded pro-
teins like Cyclin D1 
150
 or matrix metalloproteinase 7 (MMP7) 
15
 was reported for IPF 
lung tissues by several studies 
26,86,145,183
. The expression of WNT1-inducible-signaling 
pathway protein 1 (WISP1), another target gene of WNT signaling, was found increased 
9 
1. Introduction 
in alveolar epithelial type II cells of IPF patients 
88
. WISP1 has been linked to the pro-
liferation and epithelial-mesenchymal transition of ATII cells and moreover to an en-
hanced expression of extracellular matrix components by human lung fibroblasts 
88
. 
In the mouse model of bleomycin-induced pulmonary fibrosis it could be demonstrated 
that MMP7-knockout 
183
 as well as WNT/β-catenin pathway inhibition via β-catenin 
small interfering RNA 
82
 or specific inhibition of WNT/β-catenin target gene transcrip-
tion 
63
 are able to protect mice from fibrosis. The latter study actually reported a rever-
sal of existing fibrotic changes 
63
. 
It has been concluded that WNT signaling represents a developmental mechanism that 
is abnormally reactivated in IPF, a principle known from cancer pathogenesis 
26,87,146
. 
 
1.2.4 Modulators of WNT signaling 
Several proteins are able to modulate WNT activity, such as Dickkopf (DKK) 
51
, 
secreted frizzled-related protein (SFRP) 
164
, WNT inhibitory factor (WIF) 
70
 or Wise 
72
. 
Two main mechanisms of interference with WNT signaling have been demonstrated. 
Thus, these factors either have the capability of direct interaction with WNT or to 
interfere with its receptors 
76,87,102
. DKK proteins belong to the second category since 
they bind LRP receptors and therefore particularly affect the WNT/β-catenin 
pathway 
102,121
. 
 
1.2.4.1 Dickkopf proteins and their interference with WNT 
There are four known Dickkopf proteins in vertebrates, DKK1-4 
91,121
. They are secret-
ed proteins sharing two cysteine rich domains, but they depict heterogeneity in structure 
and function 
91,121
. DKK1 was initially discovered as WNT inhibitor and head-inducer 
in Xenopus embryos, where microinjection of DKK1 mRNA led to formation of en-
larged heads 
51
. DKK2 and DKK4 are capable of WNT inhibition as well, whereas 
DKK2 can additionally act as a WNT activator, depending on molecular environment 
and cellular context 
17,91,96,103,174
. 
Modulation of the WNT/β-catenin pathway is possible due to the ability of DKKs to 
bind LRP receptors. This has been demonstrated for DKK1 and DKK2 
8,17,105,147
. Addi-
tionally it has been discovered that DKK1 and DKK2 have high affinity for the Kremen 
(KRM) receptors KRM1 and KRM2 
104
, single transmembrane-spanning proteins with a 
kringle domain in their extracellular region 
119
. Although it seems that KRM proteins 
10 
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are not necessarily required for WNT regulation via DKK 
121,169
, the presence of KRM 
receptors enhances the ability of DKK proteins 1, 2 and 4 to inhibit WNT signal-
ing 
103,104
. DKK2 with its context-dependent repressive or activating ability can actually 
be converted into a pure WNT inhibitor via interaction with KRM2 
103
. 
DKK3 demonstrates the highest discrepancy of the four family members in structure as 
well as in function 
91,103
. It seems neither capable of binding LRP 
105
, nor KRM 
103,104
, 
nor was it considered to interfere with WNT signaling 
91,103,174
. However, recent studies 
have reported WNT modulatory capabilities for DKK3, as it inhibited β-catenin accu-
mulation in an osteosarcoma cell line 
66
 and reduced WNT/β-catenin target gene tran-
scription in lung cancer cell lines 
178
. So far, the exact mode of action remains unknown. 
As mechanism of interference with WNT signaling it has been suggested that DKK 
proteins 1, 2 and 4 are able to form a ternary complex with LRP and KRM, which is 
removed from the cell surface via endocytosis 
104,138
. Since LRP is no longer available 
for WNT binding, activation of the WNT/β-catenin pathway is prevented. However, 
there is contradictory data concerning the LRP internalization upon DKK stimulation. 
Authors of a more recent work criticize the usage of LRP6 overexpression in previous 
studies 
148
. They favor the mere binding of DKK to LRP as sufficient mechanism for 
WNT modulation when experiments are performed at endogenous LRP6 levels 
148
. 
 
    A.            B. 
 
 
 
Figure 4.  Mechanism of DKK interference with WNT. 
(A) WNT interacts with FZD and LRP receptors to initiate canonical WNT signaling. 
(B) DKK inhibits canonical WNT signaling by binding to LRP and KRM. 
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1.2.4.2 Dickkopf in the lung and in fibrosing diseases 
Dickkopf proteins have been related to several diseases, for example DKK1 has been 
demonstrated to impair bone formation and to influence joint remodeling in rheumatoid 
arthritis 
37,115
. It is overexpressed in several types of cancer 
44,140
 and it is also thought to 
promote osteolytic bone metastases 
132
. 
Concerning the lung, DKK proteins seem to influence organ development and have 
been related to malignancies. In detail, it has been demonstrated that DKK1 is able to 
inhibit WNT/β-catenin signaling in the embryonic mouse lung and causes defects in 
distal airway and pulmonary vasculature formation 
34,151
. DKK1 and DKK3 have both 
been related to lung cancer. More precisely, DKK1 expression was found increased in 
several lung cancer samples and it has been considered as a biomarker for lung carci-
noma 
149,175
. Anti-DKK1 is able to inhibit the growth of lung cancer cell lines in vitro 
and in a murine tumor graft model 
140
. DKK3 expression was shown to be decreased in 
many human non-small-cell lung carcinoma (NSCLC) tissues and it has recently been 
suggested to prevent lung cancer cell growth by inhibition of the WNT/β-catenin path-
way in vitro 
109,178
. 
The role of DKK proteins in IPF had not been addressed before, but DKK1 has already 
been related to other fibrosing processes. Investigations on rat hepatic stellate cells and 
on a mouse model of cholestatic liver fibrosis have revealed an antifibrotic effect of 
DKK1 via WNT inhibition 
23. DKK1 also inhibited β-catenin accumulation in irradiated 
primary mouse fibroblasts, which is of importance since β-catenin is suggested to 
promote irradiation-induced fibrosis 
59
. Furthermore, DKK1 mediated WNT inhibition 
was suggested to prevent renal fibrosis, because it decreased myofibroblast activation 
and collagen deposition in a mouse model of obstructive nephropathy 
62
. A recent study 
has demonstrated that overexpression of DKK1 in transgenic mouse models can inhibit 
experimentally induced skin fibrosis, a fibrosing process suggested to result from an 
activated crosstalk between the transforming growth factor-β (TGF-β) and the WNT/β-
catenin signaling pathway 
4
. 
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1.3 Aim of the study 
The pathogenetic mechanisms underlying idiopathic pulmonary fibrosis are still not 
clarified. Impairment of the lung epithelium and epithelial-mesenchymal interactions 
are assumed to drive disease progression, but the exact mechanisms and mediators have 
to be further elucidated. A better understanding of the cellular and molecular processes 
would certainly contribute to an improvement in therapeutic strategies for this fatal 
disease. 
The abnormal activation of the WNT/β-catenin pathway in the lung tissue of IPF pa-
tients seems to be a promising research subject. Even more since inhibition of its target 
genes’ transcription has been demonstrated to prevent bleomycin-induced pulmonary 
fibrosis in mice 
63,82,183
. Therefore regulators of WNT/β-catenin signaling are of particu-
lar interest. 
Dickkopf proteins can effectively modulate the WNT/β-catenin signal transduction cas-
cade and they have already demonstrated antifibrotic capabilities in mouse models of 
cholestatic liver fibrosis, renal fibrosis and skin fibrosis 
4,23,62
. However, scarcely any-
thing is known about their expression in healthy adult lungs, even less in IPF lungs. 
Thus, the aim of this study was to reveal and to compare the expression and localization 
of DKK proteins and their receptors in unaffected adult lungs and IPF lungs to provide a 
more detailed picture of WNT signaling and its modulation in IPF. 
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2 Material and Methods 
2.1 Material 
2.1.1 Human lung tissue 
Lung tissue biopsies were obtained from 15 IPF patients with histological usual intersti-
tial pneumonia (UIP) pattern (4 females, 11 males; age (mean ± standard deviation 
(stdev)): 58 years ± 10 years, vital capacity (VC) (mean ± stdev): 48 % ± 10 %, total 
lung capacity (TLC) (mean ± stdev): 50 % ± 7 %, diffusing capacity of the lung for CO 
per unit of alveolar volume (DLCO/VA) (mean ± stdev): 23 % ± 4 % (all in % predicted), 
additional nasal oxygen supplementation (O2): 2-4 l/min, partial pressure (Pa) of O2 / 
CO2 in the arterialized ear lobe blood sample: PaO2: 36–71 mmHg, PaCO2: 33-65 mmHg) 
and 13 organ donors (6 females, 7 males; age (mean ± stdev): 42 years ± 19 years). For 
individual patient characteristics see table 1 (chapter 10.1). After explantation, tissue 
samples were immediately snap-frozen or placed in 4 % (w/v) paraformaldehyde. The 
study protocol was approved by the Ethics Committee of the Justus-Liebig-University 
School of Medicine, Giessen, Germany (AZ 31/93). Informed consent in written form 
was obtained from each subject. 
 
2.1.2 Human bronchoalveolar lavage fluid (BALF) 
Flexible fiber-optic bronchoscopy with extraction of bronchoalveolar lavage fluid was 
performed in a standardized manner by a physician at the Department of Medicine of 
the Justus-Liebig-University Giessen, Germany, in 2006 and 2007. Informed consent 
was obtained from each subject. The group of IPF patients consisted of 9 males (age 
(mean ± stdev): 68 years ± 6 years, VC (mean ± stdev): 59 % ± 19 %, TLC (mean ± 
stdev): 59 % ± 14 %, DLCO/VA (mean ± stdev): 55 % ± 15 %, additional nasal oxygen 
supplementation (O2): 0-5 l/min, PaO2: 45-90 mmHg, PaCO2: 34-46 mmHg). Individual 
patient characteristics are shown in table 2 (chapter 10.2). The control group consisted 
of 4 healthy, non-smoking volunteers without a history of cardiac or lung disease (med-
ical students from the Medical School of the Justus-Liebig-University Giessen, Germa-
ny). 
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2.1.3 Cell lines 
cell line specification company, catalog number 
BEAS-2B human bronchial epithelial 
cell line (non-cancerous) 
European Collection of Cell Cultures, 
Porton Down, UK; 95102433 
 
2.1.4 Antibodies 
2.1.4.1 Primary antibodies 
Antibodies used for Western blot analysis (WB) and immunohistochemistry (IHC) are 
listed with the respective dilutions. 
 
antibody origin company, catalog number dilution 
WB 
dilution 
IHC 
anti-DKK1 rabbit Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, sc-25516 
1:200 1:50 
anti-DKK2 rabbit Abcam, Cambridge, UK, 
ab38594 
1:200 - 
anti-DKK4 rabbit Abcam, Cambridge, UK, 
ab38589 
1:200 - 
anti-DKK4 rabbit Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, sc-25519 
- 1:100 
anti-KRM1 goat R&D Systems, Minneapolis, 
MN, USA, AF2127 
1:1000 1:100 
anti-KRM2 rabbit Sigma-Aldrich, St. Louis, 
MO, USA, HP A003223 
1:200 1:100 
anti-LRP5 rabbit Abcam, Cambridge, UK, 
ab38311 
- 1:100 
anti-β-actin rabbit Cell Signaling Technology, 
Beverly, MA, USA, #4967 
1:1000 - 
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2.1.4.2 Secondary antibodies 
antibody origin company, catalog number dilution 
anti-rabbit IgG, 
HRP conjugated 
goat Pierce Protein Research Products, 
Rockford, IL, USA,#31460 
1:3000 
anti-goat IgG, 
HRP conjugated 
rabbit Pierce Protein Research Products, 
Rockford, IL, USA, #31402 
1:3000 
biotinylated 
anti-rabbit IgG 
goat Invitrogen, Carlsbad, CA, USA, 
Histostain-Plus Kit 
ready to use 
biotinylated 
anti-goat IgG 
rabbit Invitrogen, Carlsbad, CA, USA, 
Histostain-Plus Kit 
ready to use 
 
2.1.5 Recombinant proteins 
recombinant protein company, catalog number 
recombinant human DKK1 R&D Systems, Minneapolis, MN, USA, 
1096-DK 
 
2.1.6 Chemicals and reagents 
product company 
Acrylamide solution, Rotiphorese
®
 Gel 30 Carl Roth GmbH, Karlsruhe, Germany 
Agarose Promega, Madison, WI, USA 
APS Promega, Madison, WI, USA 
β-Mercaptoethanol Sigma-Aldrich, Saint Louis, MO, USA 
Bromphenol Blue Sigma-Aldrich, Saint Louis, MO, USA 
BSA Sigma-Aldrich, Saint Louis, MO, USA 
Chemiluminescent Substrate 
SuperSignal
®
 West Pico  
Pierce Protein Research Products, USA 
Citrate Buffer 20 x Invitrogen, Carlsbad, CA, USA 
Complete™ Protease Inhibitor Roche, Basel, Switzerland 
Dkk-1 DuoSet ELISA, human, DY1906 R&D Systems, Minneapolis, MN, USA 
DNA Ladder 100 bp Promega, Madison, WI, USA 
DNA loading dye Blue/Orange, 6 x  Promega, Madison, WI, USA 
dNTP PCR Nucleotide Mix 10 mM Promega, Madison, WI, USA 
EDTA Promega, Madison, WI, USA 
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EGTA Sigma-Aldrich, Saint Louis, MO, USA 
Ethanol absolute Sigma-Aldrich, St. Louis, MO, USA 
Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
Glycerol Merck Biosciences, Darmstadt, Germany 
Glycerol gelatine, Kaiser’s Merck Biosciences, Darmstadt, Germany 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
H2O2 30 % (w/w) Perdrogen
®
 Sigma-Aldrich, St. Louis, MO, USA 
Hematoxylin, Mayer’s Sigma-Aldrich, St. Louis, MO, USA 
HEPES Buffer solution 1 M PAA Laboratories, Pasching, Austria 
Histostain-Plus Kit Invitrogen, Carlsbad, CA, USA 
LHC-9 Invitrogen, Carlsbad, CA, USA 
Methanol Sigma-Aldrich, Saint Louis, MO, USA 
MgCl2 (25 mM) Applied Biosystems, Wellesley, MA, USA 
MgCl2 (50 mM) Invitrogen, Carlsbad, CA, USA 
Milk powder (blotting grade) Carl Roth GmbH, Karlsruhe, Germany 
NaCl Merck Biosciences, Darmstadt, Germany 
Paraformaldehyde Sigma-Aldrich, Saint Louis, MO, USA 
PBS PAA Laboratories, Pasching, Austria 
PCR Buffer 10 x (without MgCl2) Applied Biosystems, Wellesley, MA, USA 
Platinum
®
 SYBR
®
 Green qPCR 
SuperMix-UDG  
Invitrogen, Carlsbad, CA, USA 
Protein Standards Precision Plus, 
prestained 
Bio-Rad, Hercules, CA, USA 
Quick Start™ Bradford 1 x dye reagent Bio-Rad, Hercules, CA, USA 
Quick Start™ Bradford Protein Assay Bio-Rad, Hercules, CA, USA 
Random Hexamers (50 µM) Applied Biosystems, Wellesley, MA, USA 
Reverse Transcriptase MuLV RT (50 U/µl) Applied Biosystems, Wellesley, MA, USA 
RNase Inhibitor Applied Biosystems, Wellesley, MA, USA 
RNase-Free DNase Set Qiagen, Venlo, Netherlands 
RNase-Free Water Qiagen, Venlo, Netherlands 
RNeasy Mini Kit Qiagen, Venlo, Netherlands 
Roti
®
-Quick-Kit Carl Roth GmbH, Karlsruhe, Germany 
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SDS Solution 10 % (w/v) Promega, Madison, WI, USA 
Streptavidin Invitrogen, Carlsbad, CA, USA 
TAE Buffer, Rotiphorese
®
 10 x Carl Roth GmbH, Karlsruhe, Germany 
TEMED Bio-Rad, Hercules, CA, USA 
Tris Carl Roth GmbH, Karlsruhe, Germany 
Triton
®
 X-100 Promega, Madison, WI, USA 
Trypsin EDTA 1 x PAA Laboratories, Pasching, Austria 
Tween
®
 20 Sigma-Aldrich, Saint Louis, MO, USA 
Xylene Sigma-Aldrich, St. Louis, MO, USA 
 
2.1.7 Equipment and Software 
product company 
Calibrated Densitometer GS-800
TM
 Bio-Rad, Hercules, CA, USA 
Chromatography paper 3MM CHR Whatman International Ltd, Maidstone, UK 
Developing machine; X Omat 2000 Kodak, Rochester, NY, USA 
Electrophoresis and Western blot 
chambers 
Bio-Rad, Hercules, CA, USA 
Fusion A153601 microplate reader Packard BioScience/PerkinElmer, 
Waltham, MA, USA 
Light microscope Leica DMIL Leica Microsystems, Wetzlar, Germany 
Light microscope Olympus BX 51 Olympus, Hamburg, Germany 
Microsoft Office Word/Excel/PowerPoint 
2007 
Microsoft Corp., Unterschleißheim, 
Germany 
NanoDrop ND-100 Spectrophotometer Peqlab, Erlangen, Germany 
Nitrocellulose membrane Bio-Rad, Hercules, CA, USA 
PCR-Thermocycler MJ Research, Waltham, MA, USA 
Quantity One 1-D analysis software Bio-Rad, Hercules, CA, USA 
Sequence Detection System Fast 7500 
and Software 
Applied Biosystems, Wellesley, MA, USA 
UV transilluminator  UVP, Upland, CA, USA 
X-ray film AGFA Curix HT1000G Plus  AGFA-Gevaert, Mortsel, Belgium 
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2.2 Methods 
2.2.1 Quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) 
2.2.1.1 RNA extraction from tissue 
RNA was extracted from lung tissue homogenates with the Roti-Quick-Kit. Tissue 
samples were homogenized in liquid nitrogen with a pestle, 2 ml of the guanidinium 
thiocyanate containing solution were added per 0.2 g of tissue. After 20 min of incuba-
tion, samples were additionally homogenized with a syringe with a 0.9 mm needle. 2 ml 
of the phenol and chloroform containing solution were added per sample. Samples were 
incubated on ice for 10 min and vortexed every 2 min. After centrifugation at 13000 rpm 
for 15 min at a temperature of 4 °C, two phases were separated. The upper, RNA-
containing phase was incubated with an equal volume of the isopropanol containing 
solution for 1 h, at a temperature of -80 °C. The centrifugation step was repeated and an 
RNA-containing pellet could be extracted. It was dissolved in a mixture of 150 µl of the 
guanidinium thiocyanate containing solution and 150 µl of the isopropanol containing 
solution and incubated for 1 h at -80 °C. Centrifugation and dissolving step were repeat-
ed. After that, samples were centrifuged at 13000 rpm for 20 min at a temperature of 
4 °C. The supernatant was removed and 500 µl of ethanol (70 % v/v in RNase-free wa-
ter) were added. Another centrifugation step was performed for 10 min and the superna-
tant was discarded. The RNA pellet was resuspended in 50 µl of RNase-free water and 
stored at a temperature of -80 °C. 
 
2.2.1.2 RNA extraction from cells 
Medium was removed from cell culture flasks and cells were washed with PBS twice. 
Cells were disrupted and detached from the plates by scraping with a rubber policeman 
after addition of β-mercaptoethanol containing RNeasy Lysis Buffer (RNeasy Mini Kit, 
preparation according to manufacturer’s protocol) and they were homogenized with a 
syringe with 0.9 mm needle. RNA extraction was performed with the silica-membrane 
column system of the RNeasy Mini Kit according to the manufacturer´s instructions. 
This included an on-column DNase digestion using the RNase-free DNase Set to addi-
tionally remove DNA contaminant. Finally the RNA isolate was eluted from the column 
by adding 35 µl of RNase free water twice and then stored at a temperature of -80 °C. 
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2.2.1.3 RNA quantification 
Quantification of the samples’ RNA concentration was performed with the NanoDrop 
spectrophotometer. Therefore the optical density (OD) of 1.5 µl of the sample was de-
termined at a wavelength of 260 nm, at which absorption correlates to the concentration 
of nucleic acids within the sample. Since the absorption at a wavelength of 280 nm cor-
relates with protein concentration, sample purity could be verified by determination of 
the RNA/protein ratio (OD260nm/OD280nm). This ratio had to lie in between 1.8 and 2.0 to 
exclude a relevant protein contamination. 
 
2.2.1.4 cDNA synthesis by reverse transcription 
For analysis of the respective mRNA levels in a sample by qRT-PCR, the RNA had to 
be transcribed in complementary DNA (cDNA) by an RNA-dependent DNA polymer-
ase (reverse transcriptase). For preparation of cDNA synthesis, 1 µg of total RNA was 
diluted with RNase-free water to a total volume of 20 µl. RNA denaturation was per-
formed by a thermocycler at a temperature of 70 °C for 10 min, followed by cooling the 
samples down for 5 min at a temperature of 4 °C. For reverse transcription, 20 µl of the 
following RT Mastermix was added to each RNA sample: 
component volume final concentration 
10 x PCR Buffer (without MgCl2) 4 µl 1 x 
MgCl2 (25 mM) 8 µl 5 mM 
dNTP PCR Nucleotide Mix (10 mM) 2 µl 0.5 mM 
Random Hexamers (50 µM) 2 µl 2.5 µM 
RNase Inhibitor (20 U/µl) 1 µl 0.5 U/µl 
Reverse Transcriptase MuLV RT (50 U/µl) 2 µl 2.5 U/µl 
ddH2O 1 µl  
 
Reverse transcription was performed with a thermocycler by the following steps at the 
indicated temperatures and durations: 
step temperature duration 
attachment of random hexamers 20 °C 10 min 
reverse transcription 43 °C 75 min 
inactivation of reverse transcriptase 99 °C 5 min 
cooling down 4 °C  
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The synthesized cDNA samples were stored at a temperature of -20 °C. 
 
2.2.1.5 Quantitative reverse transcription polymerase chain reaction 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed 
using fluorogenic SYBR Green. 2 µl of the previously synthesized cDNA were trans-
ferred to the wells of a 96 well plate, each well filled with 23 µl of the following qRT-
PCR Mastermix: 
component volume final concentration 
Platinum
®
 SYBR
®
 Green qPCR SuperMix-UDG 13 µl  
MgCl (50 mM) 1 µl 2 mM 
forward primer (10 µM) 0.5 µl 200 nM 
reverse primer (10 µM) 0.5 µl 200 nM 
ddH2O 8 µl  
 
Amplification and detection were carried out with the Sequence Detection System Fast 
7500 via performance of 45 cycles of the following steps at the indicated temperatures 
and durations: 
step temperature duration 
activation of polymerase enzyme 50 °C 2 min 
first denaturation 95 °C 5 min 
second denaturation 95 °C 5 s 
annealing 59 °C 5 s 
elongation 72 °C 30 s 
dissociation step 1 95 °C 15 s 
dissociation step 2 60 °C 1 min 
dissociation step 3 95 °C 15 s 
dissociation step 4 60 °C 15 s 
 
By denaturation, double-stranded DNA gets separated into single strands. During the 
annealing phase, primers bind to the respective sequences at the single DNA strands. A 
new DNA strand is synthesized by the DNA-dependent DNA polymerase enzyme dur-
ing the elongation step. 
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2.2.1.6 Primers 
GenBank from the National Center for Biotechnology Information (NCBI) and the 
primer express 3.0 software were used to create adequate primer sequences for target 
and reference genes. Detailed information on primer sequences are listed in table 3 
(chapter 10.3). Each primer was tested with an undiluted, a 1:8 and a 1:64 diluted sam-
ple to determine primer efficiency for a range of template concentrations. All primers 
were utilized at a final concentration of 200 nM. 
 
2.2.1.7 Data evaluation 
Since SYBR Green binds sequence independently to double stranded DNA and leads to 
an increase in fluorescence, the amount of synthesized DNA is proportional to the fluo-
rescent signal. Fluorescence intensity is measured at the end of the elongation step of 
each cycle and a curve depicting the increase in DNA is created. Each sample was 
measured twice and the values were averaged. Empty controls containing the respective 
qRT-PCR Mastermix without addition of cDNA were measured at each plate. 
Target-DNA levels of each sample were normalized to DNA levels of a reference gene 
within the respective sample amplified at the same plate. As reference gene, the 
constitutively and ubiquitously expressed hypoxanthine-guanine phosphoribosyltrans-
ferase 1 (HPRT1) 
33,99
 was used in all qRT-PCR reactions. Comparing measurement of 
target and reference DNA levels was performed in the exponentially increasing segment 
of the curve before saturation had occurred and a threshold was set in this area. For 
target and reference gene, the same threshold was used for all samples. The cycle 
number at which the fluorescent signal reached the threshold was expressed as Ct 
(threshold cycle). These Ct values are in inverse proportion to the initial amount of 
RNA within the sample. The relative transcript abundance in a sample is expressed as 
Ct value (Ct = Ctreference – Cttarget). Therefore positive Ct values of the present study 
represent an elevated expression of the target gene compared to the reference gene, 
while negative Ct values depict a target gene expression lower than the expression of 
the reference gene. Relative changes of transcript levels in IPF samples compared to 
donor samples are given as Ct values (Ct = CtIPF – Ctdonor). The Ct values 
approximately correspond to the binary logarithm of the fold change. 
The purity and length of the DNA products were verified by melting curve analysis and 
agarose gel electrophoresis. 
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2.2.1.8 Melting curve analysis 
Melting curve analysis by the Fast 7500 System was used to verify the purity of the 
specific DNA product, since the melting temperature depends on product length and the 
amount of GC basepairs in the double stranded DNA. After 45 cycles, the melting point 
was identified by slowly increasing heat. The peak of fluorescence-intensity-change, 
induced by the release of SYBR Green during the melting process, indicated the spe-
cific melting temperature of one product. 
 
2.2.1.9 DNA agarose gel electrophoresis 
qRT-PCR products were displayed by agarose gel electrophoresis in order to check the 
product size to ensure that the correct template had been amplified. Therefore agarose 
gels were prepared: 
2 % agarose gel: 1 x TAE buffer  
2 % agarose (w/v) 
0.5 µg/ml ethidium bromide 
 
PCR product samples were mixed 5:1 with 6 x DNA loading dye Blue/Orange and 
transferred onto the gel. For each PCR product, two different samples as well as one 
empty control sample were applied. A 100 bp DNA ladder was run at the same gel. Gels 
were run in an electrophoresis chamber filled with 1x TAE buffer (Tris, acetic acid and 
EDTA) at 100 V for about 1 h. DNA bands were analyzed under ultraviolet lighting 
conditions. 
 
2.2.2 Western blot analysis 
Western blot analysis was performed on total protein extracts of lung tissue homoge-
nates from donors and IPF patients.  
 
2.2.2.1 Protein extraction and quantification 
The lung tissue was homogenized in liquid nitrogen with a pestle and 1 ml lysis buffer 
was added per 0.1 g of tissue. After 5 min of incubation, a syringe with 0.9 mm needle 
was used for further homogenization. Samples were kept on ice for 30 min and vortexed 
every 5 min. By centrifugation at 12.000*g at a temperature of 4 °C for 10 min, the pro-
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tein containing supernatant was separated from the tissue homogenate. The Supernatant 
was collected and stored at a temperature of -20 °C. 
 
Lysis buffer:  20 mM Tris pH 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1 % Triton X-100  
2 mM Na3VO4 
1:25 Complete™, protease inhibitor mix 
 
Protein quantification of each sample using the Quick Start Bradford Protein Assay was 
performed via spectrophotometric measurement with a Fusion A153601 Reader at a 
wavelength of 570 nm. Wells of a 96 well plate were filled with 200 µl of Quick Start 
Bradford dye reagent and 10 µl of the 1:20 diluted protein sample were added to a 
respective well. Additionally, six diluted BSA samples (0.05, 0.1, 0.2, 0.3, 0.4 and 
0.5 µg/µl) as well as negative controls containing Bradford dye and 1:20 diluted protein 
lysis buffer were measured at the same plate. Measurement was done after an 
incubation period of 15 min. Duplicates of BSA standards, protein samples and controls 
were measured and values were averaged. By comparing protein sample values to the 
BSA standard curve via interpolation, the protein concentration of each sample was 
calculated. 
 
2.2.2.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate proteins by size, SDS polyacrylamide gel electrophoresis was performed. 
Therefore, the required volume of each protein sample was calculated to reach a total 
amount of 25 µg protein for every loading sample. Equivalent volumes of SDS contain-
ing 2 x Sample Buffer were added to the proteins and samples were denaturated at a 
temperature of 95 °C for 10 min. Samples were loaded onto a polymerized gel, consist-
ing of a 15-well stacking gel on top of a resolving gel. As molecular weight size mark-
ers, 5 µl of protein standards were run at the same gel. Proteins were kept on ice in be-
tween the working steps. Gels were run in an electrophoresis chamber filled with Run-
ning Buffer at 110 V. 
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Resolving gel:          Stacking gel: 
10 % acrylamide/bisacrylamide     5 % acrylamide/bisacrylamide 
375 mM Tris-HCl pH 8.8       125 mM Tris-HCl pH 6.8 
0.1 % (w/v) SDS         0.1 % (w/v) SDS 
0.1 % (w/v) APS         0.1 % (w/v) APS 
0.1 % (v/v) TEMED        0.1 % (v/v) TEMED 
The used acrylamide solution contained acrylamide : bisacrylamide in a 37.5 : 1 ratio. 
 
2 x Sample Buffer:        Running Buffer: 
100 mM Tris-HCl pH 6.8       25 mM Tris 
4 % (w/v) SDS         250 mM glycine 
0.2 % (w/v) bromphenol blue      0.1 % (w/v) SDS 
20 % (v/v) glycerol 
100 nM DTT 
 
2.2.2.3 Immunoblotting 
For further analyses, the separated proteins had to be transferred onto a nitrocellulose 
membrane by using a Western blot electrophoresis chamber. Packing of the gel and ni-
trocellulose membrane into a cassette with chromatography papers and sponges was 
performed in Transfer Buffer to avoid air bubbles. The cassette was put into an electro-
phoresis chamber filled with Transfer Buffer and the transfer was done at 120 V for 1 h. 
An icebox was used to cool the chamber during the blotting process. 
 
2.2.2.4 Protein detection 
Nitrocellulose membranes were washed in Washing Buffer (2 x 5 min) and kept in 
Blocking Buffer for about 1 h. Incubation with the primary antibody was performed 
overnight at a temperature of 4 °C with a specific dilution of each antibody in Blocking 
Buffer (primary antibodies and their dilutions are listed in chapter 2.1.4.1). After a 
washing step (3 x 10 min with Washing Buffer), the membrane was incubated with a 
dilution of the adequate horseradish peroxidase (HRP)-conjugated secondary antibody 
in Blocking Buffer for 1 h (secondary antibodies and their dilutions are listed in chapter 
2.1.4.2). By performing these steps, primary and secondary antibodies got attached to 
the specific protein bands. After a second washing step (5 x 10 min), the membrane was 
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ready for protein detection. For visualization of protein bands, the Chemiluminescent 
Substrate SuperSignal West Pico was applied according to the manufacturer’s instruc-
tions. An X-ray film was exposed to the membrane and developed. All incubation and 
washing steps were performed at room temperature unless it is indicated otherwise. 
Before reusing the nitrocellulose membrane for an additional protein detection, they 
were incubated with Stripping Buffer in a water bath at a temperature of 52 °C for 8 min 
and were washed with Washing Buffer afterwards. Subsequent detection of β-actin at 
each membrane served as a control for an equal protein loading. 
 
Transfer Buffer:         Washing Buffer: 
25 mM Tris          PBS (1 x) 
192 mM glycine         0.1 % (v/v) Tween 20 
20 % (v/v) methanol 
 
Blocking Buffer:         Stripping Buffer: 
PBS (1 x)           100 mM β-mercaptoethanol 
0.1 % (v/v) Tween 20        62.5 mM Tris pH 6.8 
5 % (w/v) skim milk powder      2 % (w/v) SDS 
 
2.2.2.5 Densitometry 
Densitometric analysis of the developed X-ray films was performed using a GS-800 
calibrated densitometer and the Quantity One 1-D analysis software. Optical density of 
β-actin loading control was used to equalize differences in total protein loading. There-
fore the relative expression level of an indicated protein is calculated as relative optical 
density (OD) (optical density of indicated protein / optical density of β-actin) for each 
sample. Changes in expression levels between the indicated groups were calculated as 
fold change of the means (OD(IPF) / OD(donor)) and were expressed as fold change ± 
SEM. 
 
2.2.3 Immunohistochemistry 
Paraffin embedded human lung tissue samples were cut to 3 µm sections and were 
mounted on slides. Immunohistochemical staining was performed with the Histostain 
Plus Kit. To remove the paraffin, slides were kept in an oven at a temperature of 48 °C 
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over night and were transferred to Xylene (3 x 10 min) afterwards. Incubation with de-
creasing ethanol dilutions (100 %, 95 %, 70 % of ethanol, 2 x 5 min each) and a washing 
step with PBS (2 x 5 min) followed, before tissue sections were treated for antigen re-
trieval. Therefore slides were placed in citrate buffer (1 x) and cooked in a water bath 
for 25 min. After cooling down, slides were washed with PBS again. Quenching of en-
dogenous peroxidase activity was performed by incubation with 3 % (v/v) H2O2 for 
20 min. After another washing step, the slides were incubated with serum blocking solu-
tion (Histostain Plus Kit, derived from a species different than the source of the in-
tended primary antibody) for 10 min. Subsequently the primary antibody was prepared 
and applied over night at a temperature of 4 °C. 
 
Primary antibody dilution: 
PBS 1 x 
1.5 % (v/v) serum blocking solution 
1 % or 2 % (v/v) primary antibody solution* 
*depending on the respective antibody dilution; primary antibodies and their dilutions 
are listed in chapter 2.1.4.1. 
 
After 30 min at room temperature and a washing step with PBS, slides were incubated 
with the species-appropriate secondary biotinylated antibody (Histostain plus Kit, sec-
ondary biotinylated antibodies are listed in chapter 2.1.4.2) for 10 min. Another washing 
step and incubation with HRP-conjugated Streptavidin for 10 min followed. After re-
moval of Streptavidin, the staining reaction was performed by incubating the slides with 
chromogen solution (Histostain Plus Kit) until red color staining was clearly visible 
under a microscope. Another washing step with PBS and counterstaining with hema-
toxylin for 8 min were performed subsequently. After washing the slides in running tap 
water for 10 min, coverslips were mounted via glycerol gelatine. The stained sections 
were examined using an Olympus BX51 microscope and pictures were taken in 3 dif-
ferent magnifications as indicated. 
 
2.2.4 Cell culture 
The human bronchial epithelial cell line BEAS-2B was maintained in 250 ml culture 
flasks filled with 10 ml LHC-9 medium in a 5 % CO2 containing atmosphere of 95-
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100 % air humidity at a temperature of 37 °C. The medium was changed every 3 days at 
least and passaging was performed at a confluence of 80-90 %. Therefore the medium 
was removed, cells were gently washed with PBS (1 x) and incubated with 3 ml of 
Trypsin EDTA. After detachment, 7 ml of fresh medium were added and 20 % of the 
cell suspension were transferred to a new culture flask. Then medium was added for a 
total amount of 10 ml suspension. 
 
2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
A human DKK1 enzyme-linked immunosorbent assay was performed on BAL fluids 
(BALF) following the company’s instructions. Wells of a 96-well microplate were 
coated with 100 µl of the diluted Capture Antibody and incubated for 12 h. Blocking 
was performed with 300 µl of Reagent Diluent for 1 h before incubating the wells with 
100 µl of the BALF samples for 2 h. Additionally, seven 2-fold serial dilutions of re-
combinant DKK1 protein standard with a high standard of 4000 pg/ml were applied at 
the same plate. Each BALF sample and the standard dilutions were tested twice. After 
incubation with 100 µl of the Detection Antibody for 2 h, Streptavidin-HRP was added 
to each well for 20 min. Then 100 µl of Substrate Solution were applied to each well for 
another 20 min. Color reaction was stopped by adding 50 µl of Stop Solution. In be-
tween the working steps, washing steps were carried out following the company’s in-
struction. Optical density was determined with a microplate reader at a wavelength of 
450 nm. To minimize the optical influence of the plate, a second measurement was done 
at 570 nm and values were subtracted from the measurement at 450 nm. Double values 
of samples and standards were finally averaged and the DKK1 protein content of BAL 
fluids was calculated by interpolation on the basis of the seven point DKK1 protein 
standard curve. 
 
2.2.6 Statistical analysis 
All numerical data are presented as mean ± SEM. All experimental values were tested 
for normal distribution and the indicated groups were compared using a two-tailed, un-
paired two-sample t-test for experiments with two groups of independent samples. Re-
sults were considered statistically significant when p < 0.05. 
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3 Results 
3.1 Expression of Dickkopf proteins and their receptors 
in the lung 
3.1.1 mRNA expression of Dickkopf proteins and their receptors 
In order to quantify the relative Dickkopf (DKK) mRNA expression levels in donor and 
IPF lungs, quantitative (q)RT-PCR was performed on whole RNA-isolates of human 
lung tissue homogenates. Samples from donors and IPF patients were compared regard-
ing their expression of DKK1-4 (n=10, each). As demonstrated in figure 5A, the mRNA 
of all four DKK proteins was detected in donor as well as in IPF specimens. While 
DKK3 presented the highest relative mRNA expression level, DKK4 showed the lowest 
mRNA expression in both, donor and IPF tissue samples. Comparison of IPF and donor 
lungs revealed significant differences in the relative transcript levels. While DKK1 and 
DKK4 presented a significantly increased mRNA expression in the fibrotic lung tissues 
(∆∆Ct (mean ± SEM): DKK1: 0.85 ± 0.36 and DKK4: 2.09 ± 0.88), DKK2 mRNA was 
significantly decreased (∆∆Ct: -0.94 ± 0.34). The transcript levels of DKK3 did not 
show a significant alteration (∆∆Ct: 0.02 ± 0.85). 
The relative mRNA expression levels of the DKK receptors low density lipoprotein 
receptor-related protein (LRP) 5 and 6 and Kremen (KRM) 1 and 2 were examined 
likewise. As depicted in figure 5B, all examined receptors were detected in donor as 
well as in IPF tissues. In both groups, KRM2 presented a lower basal expression level 
than KRM1 and the LRP receptors. While the expression of KRM1 mRNA in IPF sam-
ples was significantly increased compared to the donor tissues (∆∆Ct: 1.31 ± 0.28), ex-
pression levels of KRM2, LRP5 and LRP6 were not significantly altered (∆∆Ct: KRM2: 
1.19 ± 0.72, LRP5: 0.06 ± 0.63 and LRP6: 0.03 ± 0.37). 
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Figure 5.  mRNA expression of Dickkopf (DKK), low density lipoprotein receptor-
related protein (LRP) and Kremen (KRM) in donor and IPF lung tissue. 
The mRNA expression of DKK1-4 (A) and of the receptors LRP5, LRP6, KRM1 and KRM2 (B) 
was analyzed in human lung tissue homogenates derived from donors (open bars) and IPF pa-
tients (black bars) by quantitative (q)RT-PCR. Results of both groups (n=10, each) are shown as 
relative mRNA expression compared to the reference gene HPRT1 (ΔCt), and presented as 
mean ± SEM, * = p < 0.05. 
3.1.2 Protein expression of Dickkopf and Kremen 
In order to examine whether the altered mRNA expression levels result in differences in 
protein expression, Western blot analysis was performed on whole protein extracts of 
donor and IPF lung tissue homogenates (n=5, each). The expression of the DKK 
proteins 1, 2 and 4, as well as of KRM1 and KRM2 was investigated. As depicted in 
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figure 6A, Western blotting revealed enhanced levels of all investigated DKK proteins 
in IPF. These results were confirmed by densitometric quantification of the respective 
protein immunoblots (figure 6B). Accordingly, DKK1 and DKK2 protein expression 
was significantly increased in IPF samples compared to donor samples (fold change 
(OD(IPF) / OD(donor)) ± SEM: DKK1: 1.45 ± 0.09 and DKK2: 1.99 ± 0.13). DKK4 protein 
was not detected in donor tissue samples at all. 
 
A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 6.  Protein expression of DKK in donor and IPF lung tissue. 
(A) Expression of the proteins DKK1, DKK2 and DKK4 in human lung tissue homogenates 
derived from donors and IPF patients (n=5, each) was determined by Western blot analysis of 
whole protein extracts. Antibodies were used as indicated, β-actin served as loading control. 
Protein immunoblots were carried out twice, a representative blot is shown. (B) The densitomet-
ric analyses of the respective protein immunoblots are shown. The relative optical density (OD) 
(optical density of indicated protein / optical density of β-actin loading control) is presented for 
donor (open bars) and IPF (black bars) tissues as mean ± SEM. DKK4 protein was not detected 
in donor tissue samples, the respective OD was not available (n/a). * = p < 0.05. 
 
The DKK receptors KRM1 and KRM2 were detected in lung tissue homogenates of 
both, donors and IPF patients (figure 7A). Both proteins depicted a high intra-group 
variability of expression levels. While the densitometric analysis of KRM1 protein re-
vealed a significantly increased expression in IPF tissue samples ((OD(IPF) / OD(donor)): 
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1.92 ± 0.06), the expression of KRM2 protein was not significantly altered ((OD(IPF) / 
OD(donor)): 1.37 ± 0.40) (figure 7B). 
 
A. 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 7.  Protein expression of KRM in donor and IPF lung tissue. 
(A) Expression of the proteins KRM1 and KRM2 in human lung tissue homogenates derived 
from donors and IPF patients (n=5, each) was determined by Western blot analysis of whole 
protein extracts. Antibodies were used as indicated, β-actin served as loading control. Protein 
immunoblots were carried out twice, a representative blot is shown. (B) The densitometric 
analyses of the respective protein immunoblots are shown. The relative optical density (OD) 
(optical density of indicated protein / optical density of β-actin loading control) is presented for 
donor (open bars) and IPF (black bars) tissues as mean ± SEM, * = p < 0.05. 
 
3.2 Localization of Dickkopf proteins and their receptors 
in the lung 
After investigations concerning the expression profile of Dickkopf proteins and recep-
tors on mRNA and protein level, their actual localization in the human lung was exam-
ined. Immunohistochemical stainings were performed on donor and IPF lung tissue sec-
tions in order to identify cells that are actually expressing these proteins. Antibodies 
with reasonable and reproducible staining results could be found for DKK1 and DKK4 
as well as for the receptors LRP5, KRM1 and KRM2. Stainings were performed at least 
twice using three different donor and IPF lung tissues for each antibody. Representative 
bronchial (A) and alveolar (B) regions are presented. As demonstrated in figure 8A, 
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DKK1 was mainly located in bronchial epithelial cells in donor (left panel) and IPF 
lungs (right panel), with a pronounced accumulation of DKK1 in basal bronchial epithe-
lial cells (figure 8A, arrows). In IPF lungs, DKK1 was furthermore located in hyper-
plastic alveolar epithelial cells (figure 8B, right panel, arrows). Besides, granulocytes 
presented staining of DKK1 protein in both, donor and IPF lung tissue sections (best 
recognizable in figure 8B, left panel). 
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Figure 8A. Localization of DKK1 protein in donor and IPF lung tissue – 
 bronchial regions. 
Immunohistochemical staining for DKK1 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative bronchial regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. Arrows indicate basal bronchial epithelial 
cells. 
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Figure 8B.  Localization of DKK1 protein in donor and IPF lung tissue – 
 alveolar regions. 
Immunohistochemical staining for DKK1 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative alveolar regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. Arrows indicate hyperplastic alveolar 
epithelial cells. 
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DKK4 protein was largely located in bronchial epithelial cells (figure 9A) and to a 
slighter extent in interstitial cells, in donor as well as in IPF lung tissues (figure 9A and 
9B). In comparison to DKK1, DKK4 expression exhibited a more equal basal-apical 
intensity in the bronchial epithelium (figure 9A), whereas its general expression pattern 
was scattered. As depicted in figure 9B, DKK4 was strongly expressed in hyperplastic 
alveolar epithelial cells in IPF (figure 9B, right panel, arrows). 
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Figure 9A.  Localization of DKK4 protein in donor and IPF lung tissue – 
 bronchial regions. 
Immunohistochemical staining for DKK4 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative bronchial regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. 
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Figure 9B.  Localization of DKK4 protein in donor and IPF lung tissue – 
 alveolar regions. 
Immunohistochemical staining for DKK4 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative alveolar regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. Arrows indicate hyperplastic alveolar 
epithelial cells. 
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LRP5 receptor was detected in the bronchial epithelium of donor (figure 10A, left 
panel) and IPF tissues (figure 10A, right panel), with predominant staining of supranu-
clear regions in columnar bronchial epithelial cells (figure 10A, left and right panel, 
arrows). In IPF, LRP5 was slightly expressed in hyperplastic alveolar epithelial cells 
(figure 10B, right panel, arrows). Moreover, immune cells presented staining of LRP5 
in donor and IPF lung tissue sections (best recognizable in figure 10B, left panel). 
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Figure 10A. Localization of LRP5 protein in donor and IPF lung tissue – 
 bronchial regions. 
Immunohistochemical staining for LRP5 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative bronchial regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. Arrows indicate supranuclear staining in 
columnar bronchial epithelial cells. 
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Figure 10B. Localization of LRP5 protein in donor and IPF lung tissue – 
 alveolar regions. 
Immunohistochemical staining for LRP5 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative alveolar regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. Arrows indicate hyperplastic alveolar 
epithelial cells. 
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The DKK-binding receptors KRM1 and KRM2 could also be detected in the lung tissue 
sections. In detail, KRM1 protein was expressed in bronchial epithelial (figure 11A) 
and smooth muscle cells (best recognizable in figure 11A, right panel, arrow) in donor 
and in IPF lungs. In IPF, the bronchial epithelium displayed a heterogeneous staining 
pattern (figure 11A, right panel) and hyperplastic alveolar epithelial cell regions showed 
expression of KRM1 protein (figure 11B, right panel, arrow). KRM1 was also found in 
alveolar macrophages (best recognizable in figure 11A and 11B, left panels). 
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Figure 11A. Localization of KRM1 protein in donor and IPF lung tissue – 
 bronchial regions. 
Immunohistochemical staining for KRM1 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative bronchial regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. An arrow indicates smooth muscle cells. 
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Figure 11B. Localization of KRM1 protein in donor and IPF lung tissue – 
 alveolar regions. 
Immunohistochemical staining for KRM1 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative alveolar regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. An arrow indicates hyperplastic alveolar 
epithelial cells. 
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KRM2 protein was detected in bronchial epithelial cells (figure 12A) in donor and IPF 
lung tissue sections, with a more scattered expression in the IPF lungs. Mucus residuals 
within the epithelium and in the bronchial lumen also depicted intense staining when 
they were present on the tissue sections (figure 12A, right panel). In IPF, hyperplastic 
alveolar epithelial cells expressed KRM2 protein (figure 12B, right panel, arrow). 
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Figure 12A. Localization of KRM2 protein in donor and IPF lung tissue – 
 bronchial regions. 
Immunohistochemical staining for KRM2 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative bronchial regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. 
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Figure 12B. Localization of KRM2 protein in donor and IPF lung tissue – 
 alveolar regions. 
Immunohistochemical staining for KRM2 protein was performed on lung tissue sections of do-
nors and IPF patients. Stainings were performed at least twice using three different donor and 
IPF lung tissues. Representative alveolar regions of donor (left panel) and IPF (right panel) 
lungs are shown in three magnifications as indicated. An arrow indicates hyperplastic alveolar 
epithelial cells. 
 
Immunohistochemical stainings of tissue sections from further donor and IPF lungs as 
supplement to the pictures illustrated here are depicted in chapter 10.4 for the respective 
antibodies. 
42 
3. Results 
3.3 WNT/β-catenin pathway components in bronchial 
epithelial cells 
Immunohistochemistry detected DKK1 and DKK4 as well as their LRP and KRM re-
ceptors to be largely located in the bronchial epithelium of donor and IPF lungs. In or-
der to investigate whether human bronchial epithelial cells can also express other key 
molecules of the WNT/β-catenin pathway and would therefore be basically capable of 
responding to WNT and DKK stimulation, the human bronchial epithelial cell line 
BEAS-2B was examined. RNA isolates of this cell line were analyzed for their mRNA 
expression of WNT/β-catenin signaling pathway components and DKK receptors by 
qRT-PCR (figure 13A, B). Additionally, the expression of WNT and DKK ligands was 
examined (figure 13C, D). Two flasks of BEAS-2B cells were tested and values were 
averaged. As depicted in figure 13A and 13B, mRNA of the examined WNT receptors 
FZD1-4, of the WNT and DKK binding receptors LRP5 and LRP6, as well as of the 
DKK receptors KRM1 and KRM2 was expressed by BEAS-2B cells (figure 13A). LRP5 
and LRP6 displayed the highest expression levels of these receptors. Key components of 
the WNT/β-catenin signaling cascade were expressed as well, with a high relative 
mRNA expression of β-catenin (β-CAT) (figure 13B). Of the examined ligands (figure 
13C, D), WNT1, WNT7b, WNT10b, as well as DKK1 and DKK3 could be detected. 
WNT1 and WNT10b mRNA was only expressed on low levels. WNT3a, DKK2 and 
DKK4 did not show an evaluable mRNA expression in the BEAS-2B RNA isolates 
(figure 13C, D). 
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Figure 13.  mRNA expression of WNT/β-catenin pathway components 
    in the BEAS-2B cell line. 
The mRNA expression of the receptors FZD1-4, LRP5, LRP6, KRM1 and KRM2 (A), of the 
WNT/β-catenin pathway components β-catenin (β-CAT), GSK3β, LEF1, TCF3 and TCF4 (B) 
and of the ligands WNT1, WNT3a, WNT7b, WNT10b (C) and DKK1-4 (D) was analyzed in 
RNA isolates of the human bronchial epithelial cell line BEAS-2B by quantitative (q)RT-PCR. 
Averaged results of 2 isolates are shown as relative mRNA expression compared to the refer-
ence gene HPRT1 (ΔCt) and are presented as mean ± SEM. WNT3a, DKK2 and DKK4 mRNA 
was not expressed, respective ΔCt values were not available (n/a). 
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3.4 DKK1 protein in bronchoalveolar lavage fluids 
The present study demonstrated that DKK1 mRNA and protein expression are increased 
in IPF compared to donor lung tissues and that DKK1 is largely located in basal bron-
chial epithelial cells. To investigate whether the epithelial localization leads to occur-
rence of DKK1 in the bronchial lumen and whether there are measurable differences 
between IPF patients and healthy controls in vivo, bronchoalveolar lavage fluids 
(BALF) were analyzed. Therefore, DKK1 protein was quantified in BAL fluids of 
healthy volunteers (n=4) and IPF patients (n=9) using an enzyme-linked immunosorbent 
assay (ELISA). As depicted in figure 14, DKK1 was expressed in the BAL fluids of 
both groups. While DKK1 levels in the BAL fluids of healthy volunteers showed a 
comparatively small divergence, the levels found in BAL fluids of IPF patients were 
widespread, varying up to a triplication of the absolute protein value between the lowest 
and the highest DKK1 concentration. However, the concentration of DKK1 protein in 
BAL fluids from IPF patients (mean ± SEM: 456 ± 55 pg/ml) was significantly in-
creased compared to the healthy controls (266 ± 11 pg/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  DKK1 protein concentration in bronchoalveolar lavage fluid. 
The DKK1 protein concentration in bronchoalveolar lavage fluids (BALF) of healthy volunteers 
(control group, open bar, n=4) and IPF patients (black bar, n=9) was quantified using an en-
zyme-linked immunosorbent assay (ELISA). The concentration of DKK1 protein is given in 
pg/ml and is presented as mean ± SEM. * = p < 0.05. 
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4 Discussion 
Idiopathic pulmonary fibrosis is a progressive and fatal lung disease that induces struc-
tural remodeling of the lungs’ architecture, causes respiratory impairment and limits 
quality of life 
36,133,158
. Due to the restricted response to pharmaceutical treatments, lung 
transplantation is currently the only option proven to notably prolong survival of IPF 
patients 
112,168
. The mechanisms of IPF have not been fully elucidated yet and new in-
sights into the pathogenesis may promote improvements of therapeutic strategies. 
Recent studies have highlighted an involvement of WNT/β-catenin signaling in IPF. So 
far, an aberrant reactivation of this developmental pathway in IPF lung tissue has been 
demonstrated 
26,86
. WNT/β-catenin signaling may contribute to disease progression, 
since knockout of the WNT target gene MMP7 
183
 as well as specific inhibition of 
WNT/β-catenin target gene transcription 63 or canonical pathway inhibition via β-
catenin small interfering RNA 
82
 in the bleomycin mouse model attenuated pulmonary 
fibrosis. Although limitations concerning the transferability of this animal model to 
some aspects of IPF pathobiology have to be taken into account 
113
, modulators of WNT 
signaling represent an attractive target in IPF research. Dickkopf proteins with their 
ability to bind WNT coreceptors of the LRP family belong to the best studied regulators 
of WNT/β-catenin signal transduction 101. 
An antifibrotic effect of DKK1 via WNT/β-catenin inhibition has already been reported 
in mouse models of cholestatic liver fibrosis 
23
 and renal fibrosis 
62
. However, the role 
of DKK proteins in IPF had not been addressed before. Therefore, the present study 
focused on the expression and localization of DKK proteins and their receptors in the 
healthy adult lung and in the lungs of IPF patients. 
 
4.1 Altered expression of DKK proteins and their receptors 
in IPF  
The present study reveals a regulation of DKK and KRM expression in IPF. The mRNA 
expression of DKK1 and DKK4 was found to be increased in IPF compared to donor 
lung tissues, consistent with elevated protein levels of DKK1 and DKK4 detected by 
Western blot analysis. The increase in DKK2 protein expression however did not match 
the decreased DKK2 mRNA levels in IPF lungs, suggesting differences in translational 
control mechanisms or protein stability. At first appearance, an increase of DKK1 and 
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DKK4 in IPF lungs seems to contradict the reported activation of WNT/β-catenin sig-
naling in IPF, considering their WNT-inhibitory capability. But actually, this finding is 
consistent with an increased WNT activation, since DKK1 
21,53,122
 and DKK4 
10,130
 have 
been identified as downstream target genes of the WNT/β-catenin pathway, in terms of 
a negative feedback mechanism. For DKK2 and DKK3, feedback-mechanisms have not 
been demonstrated yet. 
Since availability of DKK receptors in the lung tissue represents a basic requirement for 
modulation of WNT/β-catenin signaling via secreted DKK proteins, the present study 
focused on the expression profile of these proteins as well. In both, donor and IPF 
lungs, mRNA expression of LRP5 and LRP6 could be confirmed by qRT-PCR. Addi-
tionally, LRP5 protein expression and localization could be demonstrated by immuno-
histochemistry. The presence of LRP6 protein in its phosphorylated form in homoge-
nates of IPF and donor lungs has been described before by Western blot analysis 
86
. 
KRM1 and KRM2 mRNA and the respective proteins KRM1 and KRM2 could also be 
detected, with an increased expression of KRM1 in IPF samples. 
When interpreting the data, it has to be taken into account that mRNA and protein ex-
pression analyses were performed on lung tissue homogenates. As presence of DKK 
proteins and their receptors is cell type dependent, expression levels are subject to the 
cellular composition of each donor and IPF sample. 
 
4.2 Localization of DKK proteins and their receptors in the 
lung tissue 
Immunohistochemical analyses supplement the data derived from lung homogenates 
with the actual, cell-type dependent localization pattern. They revealed DKK1 and 
DKK4 to be largely located in the bronchial epithelium in donor as well as in IPF lung 
tissue sections. Additionally, hyperplastic alveolar epithelial cells in IPF exhibited in-
tense staining for these DKK proteins. Regarding the WNT-target-gene character of 
DKK1 and DKK4, this observation is compatible with the report on nuclear β-catenin 
accumulation and therefore with active WNT/β-catenin signaling within these cells 26. It 
has to be mentioned that the observed expression of DKK4 protein is inconsistent with 
the protein expression pattern detected by Western blot analysis, which did not depict 
DKK4 protein expression in the donor samples. However, it has to be taken into consid-
eration that samples of different donors had to be used for the two experiments, more-
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over different DKK4 antibodies. For interpretation of the immunohistochemical data 
presented in the present study, it has to be noted that stainings of donor and IPF tissue 
sections are not quantitatively comparable, since exposure to the chromogen solution 
was performed until red color staining for each section was clearly visible under a mi-
croscope. 
Interestingly, immunohistochemical staining for the receptors LRP5, KRM1 and KRM2 
revealed striking similarities to the expression pattern of their own ligands. All of the 
investigated receptors were predominantly located in the bronchial epithelium in both, 
donor and IPF lungs and additionally in hyperplastic alveolar epithelial cells in the fi-
brotic lungs. This corresponds to the observed expression pattern of DKK1 and DKK4 
in the present study. Furthermore, these observations are in line with the previously re-
ported expression patterns of WNT1, WNT3a and GSK3β, whose presence in lung tis-
sue also included the expression by bronchial epithelial cells and by hyperplastic ATII 
cells in IPF lungs 
86
. Additionally, the analysis of the human bronchial epithelial cell 
line BEAS-2B in the present study demonstrated that human bronchial epithelial cells 
are able to express other key components of the WNT/β-catenin signaling cascade, as 
well. Taken together, these data indicate that autocrine and paracrine effects of the se-
creted DKK proteins are most likely the major type of interference with WNT in the 
lung epithelium. 
The detection of KRM proteins in the lung epithelium has to be evaluated in the context 
of recent findings. While some authors support the theory of DKK, LRP and KRM 
forming a ternary complex that undergoes endocytosis 
104,138
, other authors favor the 
mere binding of DKK to LRP without enhanced removal of LRP from the plasma 
membrane as sufficient mechanism of WNT inhibition 
148
. Additionally, recent investi-
gations in KRM-knockout mice and cultured cells have highlighted that KRMs are not 
necessarily required for WNT modulation via DKK 
40,169
. Another study in Xenopus 
even suggested a DKK-independent role for KRM in WNT modulation via direct bind-
ing to LRP, as KRM was able to activate WNT in the absence of DKK1 
60
. Neverthe-
less, KRM receptors bind DKK proteins 
104,169
 and their ability to enforce the WNT in-
hibitory function of DKK proteins has been demonstrated 
103,104
. On that account it has 
been suggested that the exact impact of KRM on WNT modulation might depend on the 
level of LRP expression within the respective cells 
169
. The present study detected both, 
KRM and LRP, in the lung epithelium. Therefore an involvement of KRM receptors in 
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WNT modulation of the lungs’ epithelial cells seems probable, but further studies are 
needed to elucidate this topic in detail. 
Notably, the bronchial epithelium partially depicted a heterogenous expression pattern 
for KRM1 and KRM2, and hyperplastic alveolar epithelial cells in IPF only exhibited a 
slight staining of LRP5. This emphasizes the importance of the microenvironmental 
composition for WNT modulation in vivo. LRP5 additionally revealed a distinct 
supranuclear accumulation in bronchial epithelial cells. This may be indicative of LRP5 
containing vesicles and is possibly linked to internalization processes which have al-
ready been reported for LRP6. Besides the presumed LRP6 endocytosis upon DKK 
stimulation 
12,104,139
 in the context of WNT inhibition, further regulatory mechanisms of 
the WNT/β-catenin pathway that are based on alterations of LRP6 internalization pro-
cesses have been described. Recent studies reported the internalization of LRP6 
78,97,176
 
as well as the inhibition of its transcription 
78
 upon stimulation with WNT3a. Further-
more, the endocytosis of LRP6 in Xenopus was suggested to be inhibited by KRM 
60
, 
but there are converse observations in transfected human cell lines 
97
. 
Based on the distinct supranuclear localization of LRP5 demonstrated in the present 
study, similar internalization and regulation processes should be taken into considera-
tion for LRP5 in the bronchial epithelium. 
 
4.3 DKK in the conducting airways 
Since DKK proteins were largely located in the lung epithelium, the present study in-
vestigated whether they appear in BAL fluids. DKK1 protein content was assessed us-
ing an enzyme-linked immunosorbent assay (ELISA) and could be detected in all sam-
ples tested. Interestingly, DKK1 expression was significantly increased in BAL fluids of 
IPF patients when compared to BAL fluids of healthy volunteers. This result is in line 
with the demonstrated increase of DKK1 mRNA and protein levels in IPF lungs. Never-
theless, it has to be mentioned that the study has limitations that have to be considered 
when interpreting the data. Since total cell number and protein content of the BAL flu-
ids is an uncontrolled factor in this experiment, the increase in detected DKK1 could 
also reflect a higher occurrence of bronchial epithelial cell debris. Another important 
concern arises from the DKK1 expression pattern revealed by immunohistochemistry, 
where besides in the epithelium, staining was also present in neutrophil granulocytes. It 
remains unclear whether this finding depicts an endogenous expression, is a conse-
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quence of their phagocytic capability or is just a remnant of endogenous peroxidase 
activity. These considerations are of interest, as neutrophils are known to be increased 
in BAL fluids of IPF patients 
1
. In some of the other immunohistochemical experiments 
performed in the present study, immonureactive cells depicted staining as well (for ex-
ample localization of LRP5 (figure 10B, left panel) and KRM1 (figure 11A and 11B, 
left panels)). Therefore an insufficient quenching of peroxidase activity in the study 
protocol might after all be the cause for a staining of the neutrophils. More detailed 
studies are required for definite evaluation of these issues. 
So far, BAL fluids are of subordinate use for the diagnosis of IPF. In some cases the 
examination of BAL fluid can contribute to the exclusion of differential diagnoses 
1,133
. 
Interestingly, previous studies reported that the insulin-like growth factor binding pro-
tein 4 (IGFBP4), which has recently been identified as inhibitor of the WNT/β-catenin 
pathway 
182
, and MMP7, another WNT/β-catenin target 30, are also increased in BAL 
fluids of IPF patients 
137,145
. It is further prominent that both proteins are located in basal 
bronchial / bronchiolar epithelial cells, according to the localization pattern of DKK1 in 
the present study 
26,145
. 
 
4.4 DKK proteins and their receptors in the lung epithelium 
The lung epithelium is of crucial interest for pathogenesis and disease progression in 
IPF, since repetitive epithelial microinjuries and inadequate repair mechanisms are con-
sidered as essential mechanisms of the fibrosing process 
22,142
. Altered phenotypes of 
alveolar epithelial cells as well as of the bronchiolar epithelium are frequent findings in 
IPF lung tissues 
25,144
 and they have been associated with abnormal WNT/β-catenin sig-
naling 
26
. The present study revealed the expression of DKK proteins and their receptors 
in the lung epithelium and raises interesting questions about their influence on the cell-
type dependent increase of WNT/β-catenin pathway activation in IPF. 
 
4.4.1 DKK proteins and their receptors in alveolar epithelial cells 
The present study identified expression of the WNT modulators DKK and KRM in hy-
perplastic alveolar epithelial cells of IPF patients. Alveolar epithelial cells (AEC) can be 
divided in type I cells (ATI), that account for 95 % of the AEC cells and type II cells 
(ATII), that account for 5 % of the AEC cells 170. The function of ATII cells, which 
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among other capabilities are able to serve as progenitor cells for damaged ATI cells 
163
, 
is impaired in IPF 
142
. Abnormal ATII cell proliferation, ATII cell apoptosis next to 
fibroblast foci and a hyperplastic phenotype of ATII cells are common findings in IPF 
lung histology 
69,142,144
. Furthermore, the alveolar epithelium and especially ATII cells 
are an important source of cytokines, including profibrotic mediators 
127,143,144
. Together 
with a dysregulation of apoptotic processes and a failure in alveolar re-epithelialization, 
these mediators are suggested to contribute to the fibrosing process 
128,159
. An enhanced 
ATII cell proliferation has been reported in a mouse model of bleomycin induced pul-
monary fibrosis 
88
 and in another recent study, the targeted injury of ATII cells in trans-
genic mice induced the occurrence of lung fibrosis 
153
. 
For the abnormal hyperplastic ATII cell type in IPF, a nuclear accumulation of β-
catenin indicating an activation of the WNT/β-catenin pathway has already been report-
ed 
26
. This observation seems to be rather specific to alveolar injury than disease-
specific, since nuclear β-catenin accumulation also occurs in other lung diseases that go 
along with alveolar damage 
26
. Additionally, components of the WNT β-catenin path-
way as well as some of the WNTs themselves show an increased expression in primary 
ATII cells of IPF patients 
86
. 
In the first place, the expression of DKK proteins in the hyperplastic cell type observed 
by the present study corresponds to the previously described activation of the WNT/β-
catenin pathway within these cells, considering the target-gene-character of DKK1 and 
DKK4. But the DKK proteins may additionally be of interest in the autocrine or para-
crine regulation of alveolar epithelial cell proliferation, as they were able to influence 
the proliferation of the human alveolar epithelial cell line A549 in a recent study per-
formed by our workgroup 
131
. A549 cells possess characteristics of alveolar epithelial 
type II cells 
98
 and WNT3a-responsiveness of A549 cells has been demonstrated be-
fore 
86,94
. The proliferation of this cell line was increased upon WNT3a stimulation 
86
. 
These data were supplemented by detection of a dose dependant inhibition of WNT-
induced A549 cell proliferation by DKK1 
131
. Interpretation of these results is limited 
by the usage of a cell line. Especially A549 epithelial cells with their adenocarcino-
matous origin may depict an altered cellular response upon WNT and DKK stimulation. 
A good possibility to clarify the impact of DKK proteins on alveolar epithelial cell pro-
liferation would certainly be the stimulation of isolated primary ATII cells. 
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4.4.2 DKK proteins and their receptors in the bronchial epithelium 
4.4.2.1 Proliferation and repair of the airway epithelium 
In contrast to other epithelia like those of gut and skin, which exhibit a high cellular 
turnover, the unimpaired lung epithelium is renewing slowly 
31,90,154
. However, the pro-
liferative activity can be markedly increased in case of epithelial injury 
31,136
. The re-
generating strategies of the airway epithelium are still not fully elucidated. Most of the 
current knowledge is based on injury models performed in mice 
32,52,100
. It is assumed 
that several resident cell populations can serve as potential progenitors for the lung epi-
thelium and possibly, but controversially debated, also some non-local cell types such 
as bone marrow derived stem cells 
52,90,100
. 
The resident progenitor cells include several cell types that are located at different com-
partments of the lung. As mentioned above, ATII cells are progenitor cells located in 
the alveoli 
90,100,163
. But besides the repair mechanisms of the alveolar cell compartment, 
epithelial proliferation and repair processes of the conducting airways are of interest for 
IPF pathogenesis as well. Bronchiolar lesions and basal cell abnormalities including 
basal cell hyperplasia and abnormal bronchiolar proliferation are frequent and specific 
findings in IPF when compared to other diffuse parenchymal lung diseases 
25
. In the 
bronchioles, specific types of Clara cells seem to possess proliferative capacity after 
epithelial injury 
49,90
. At the bronchoalveolar junction, further cells that express Clara 
cell and ATII cell markers (bronchioalveolar stem cells, BASC) have been suggested to 
serve as epithelial progenitors 
80
, but their existence is critically discussed 
90
. Addition-
ally, multipotent resident stem cells have recently been identified in the distal airways 
of adult human lungs. These cells were able to generate bronchioles, alveoli and vascu-
lature after injection into cryoinjured mouse lungs 
74
. In the tracheal and bronchial epi-
thelium, basal cells and cells that originate from submucosal airway glands are seen as 
potential progenitor populations 
52,100
. It was proposed that ciliated cells themselves 
could serve for epithelial regeneration by transdifferentiation 
129
, but there are converse 
findings 
134
. 
The present study identified Dickkopf proteins and their receptors to be largely located 
in the bronchial epithelium. An impact of WNT/β-catenin signaling on regeneration and 
proliferation of the bronchial and bronchiolar epithelium is recently under discussion. 
Concerning the bronchiolar epithelium, one recent study reported the WNT/β-catenin 
pathway to be activated during epithelial regeneration and to promote an expansion of 
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bronchoalveolar stem cells at the bronchoalveolar junction 
181
. Conversely, another pub-
lication stated that β-catenin pathway activation is not necessary for bronchiolar epithe-
lial proliferation or repair mechanisms 
179
. Concerning the bronchial epithelium, an in-
creased nuclear accumulation of β-catenin indicating an activated WNT/β-catenin sig-
naling pathway was detected in an in vitro model of bronchial epithelial repair 
156
. The-
se studies were performed using human bronchial epithelial cell lines as well as primary 
human bronchial epithelial cells 
156
. 
Therefore DKK proteins as modulators of the WNT/β-catenin signaling cascade are of 
interest concerning the regulation of maintenance and regeneration processes in the 
bronchial and bronchiolar epithelium. In the present study, all of the investigated DKK 
proteins and receptors were located in bronchial epithelial cells and interestingly, DKK1 
depicted a pronounced and distinct accumulation in basal bronchial epithelial cells, one 
of the cell populations considered as epithelial progenitors. 
 
4.4.2.2 DKK1 in basal cells of the bronchial system 
The function of basal cells as bronchial epithelial progenitors was examined in 
mice 
68,136
, as well as in an in vitro assay of primary human basal bronchial epithelial 
cells 
136
. A subset of them is considered to be capable of generating a differentiated air-
way epithelium after epithelial injury 
68,136
. Basal bronchial epithelial cells can be found 
throughout the conducting airways of the human lung including the bronchioles, but 
occur less frequently in the distal parts of the bronchial tree 
118,136
. Particularly with re-
gard to the small airways, this cell population has gained interest in IPF histopathology. 
Proliferative bronchiolar abnormalities were demonstrated to be specific findings in IPF 
lungs when compared to other IIP entities and healthy lung tissue 
25
. Those abnormali-
ties included atypical and hyperplastic basal bronchiolar epithelial cells as well as an 
abnormal occurrence and superficial location of basal cells at the bronchoalveolar junc-
tions 
25,26
. These areas have been connected to the formation of characteristic 
histomorphological changes in IPF lungs like honeycomb cysts (dilated bronchioles) 
and bronchiolization (ectopic localization of bronchiolar epithelial cells in the alveolar 
space) 
25,26
. Furthermore, those lesions and especially the basal cell population present-
ed an accumulation of nuclear β-catenin and an elevated expression of the WNT/β-
catenin target gene MMP7, indicating an activation of this signaling cascade 
26
. 
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Immunohistochemical stainings of the present study revealed an accumulation of DKK1 
protein in basal epithelial cells of donor and IPF lungs and brought up the question on a 
possible influence of DKK1 on bronchial epithelial cell proliferation. It could be 
demonstrated that the human bronchial epithelial cell line BEAS-2B expresses mRNA 
of major components of the WNT/β-catenin pathway and of the DKK receptors. There-
fore bronchial epithelial cells seem to be able to react on WNT and DKK stimulation. In 
consequence of the findings of the present study, our workgroup performed experiments 
on the proliferation of BEAS-2B cells and could demonstrate a dose-dependent regula-
tion of WNT-induced BEAS-2B cell proliferation by DKK1 
131
. Stimulation with 
Wnt3a caused an increase of BEAS-2B cell proliferation and this effect could be inhib-
ited by high concentrations of DKK1. Unexpectedly, low concentrations of DKK1 alone 
led to an increase in proliferation of BEAS-2B cells 
131
. Whether this effect is accom-
plished by β-catenin pathway induced proliferation or is a WNT/β-catenin-independent 
action of DKK1 remains unclear. It was shown that DKK1 possesses WNT/β-catenin 
independent functions in the embryogenesis of Xenopus 
89
 and can also modulate non-
canonical WNT signaling, what could be demonstrated in Xenopus embryos 
19,20
 and in 
human mesothelioma cell lines 
92
. 
The results suggest that DKK proteins may be of interest for the molecular mechanisms 
underlying proliferation and maintenance of the bronchial epithelium and especially for 
IPF histopathology, where aberrantly activated canonical WNT signaling is found at 
sites of atypical and proliferative basal epithelial cell phenotypes 
26
. However, interpre-
tation of the results is limited by the usage of a cell line. As demonstrated by the present 
study, the mRNA expression profile of BEAS-2B cells does not exactly reflect the ex-
pression of WNT/β-catenin and DKK components in donor lungs revealed by immuno-
histochemistry. BEAS-2B cells express LRP5, KRM1 and KRM2 mRNA according to 
the immunohistochemical localization of the respective proteins in the bronchial epithe-
lium. They also express mRNA of key components of the WNT/β-catenin pathway like 
β-catenin and GSK3β, consistent with a previous report on the localization of the re-
spective proteins in bronchial epithelial cells 
86
. But BEAS-2B cells exhibit some differ-
ences concerning the expression pattern of the ligands when compared to the bronchial 
epithelium of an adult lung. WNT3a was not detected in BEAS-2B RNA isolates in the 
present study, but WNT3a protein could be identified in selected bronchial epithelial 
cells of donor lung tissues by immunohistochemistry in a previous experiment 
86
. Like-
wise, BEAS-2B cells did not express DKK4 mRNA, while immunohistochemical 
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stainings of the present study identified DKK4 protein to be located in the bronchial 
epithelium of the adult lung. Basically, these findings should not influence the capabil-
ity of BEAS-2B cells to react on WNT or DKK stimulation, but they indicate differ-
ences between this cell line and an entire bronchial epithelium. Therefore, further stud-
ies will have to be performed to elucidate the influence of DKK1 on bronchial and 
bronchiolar epithelial cell proliferation. Proliferation assays on primary basal bronchial 
epithelial cells would certainly contribute to a better understanding of WNT and DKK 
function in epithelial cell proliferation in vivo. 
 
4.4.2.3 Basal bronchial epithelial cells and malignancies 
Besides their physiological proliferative capacity, basal cells are considered as origin of 
squamous metaplasia and dysplasia, which are regarded as facultative preneoplastic 
lesions for the squamous cell carcinoma (SCC) of the lung 
173
. Therefore, the distinct 
expression of DKK1 in basal bronchial epithelial cells and its influence on bronchial 
epithelial cell proliferation might also represent interesting aspects for lung cancer re-
search. Especially since non-small-cell lung carcinomas (NSCLC), including SCC, have 
already been associated with an activation of WNT signaling 
87,109,166
. WNT1 and 
WNT2 were found overexpressed in some NSCLCs / SCCs 
61,177
 and WNT1 was con-
nected to NSCLC proliferation 
71
. Other components of the WNT/β-catenin pathway 
like Dishevelled 3 (DSH3) and lymphoid enhancer-binding factor 1 (LEF1) were over-
expressed as well 
35,162
, while the WNT inhibitors WNT inhibitory factor 1 (WIF1) and 
secreted frizzled-related protein 1 (SFRP1) were frequently found down-regulated in 
NSCLC tissues 
35,46,109,110,166
. Furthermore, an inhibition of WNT1 and WNT2 proteins 
could induce apoptosis of NSCLC cell lines 
61,177
. DKK1 expression has already been 
found increased in several lung cancer samples including SCC 
175
. So DKK1 as inhibi-
tor of WNT/β-catenin signaling might be of particular interest for the formation and 
growth of dysplasia and malignant transformations of the basal bronchial progenitor cell 
population. 
Interestingly, metaplastic epithelia and in particular the squamous metaplasia are fre-
quent findings in IPF lungs 
25,65,85
 and the squamous cell lung carcinoma is a frequently 
observed histological type of lung cancer in IPF patients 
6,77
. Squamous metaplasia and 
invasive carcinoma in IPF patients are often located peripherally, in areas of fibrosis 
and honeycombing 
6,25,65
, a structural abnormality that has already been related to the 
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occurrence of atypical basal cells that depict an abnormal activation of WNT/β-catenin 
signaling 
26
. 
 
4.5 Conclusions and future perspectives 
Aim of the present study was to examine the expression and localization of the WNT 
modulatory DKK proteins and their LRP and KRM receptors in the adult lung and in 
IPF patients. Expression of these proteins could be confirmed in both examined groups. 
DKK1, DKK4 and KRM1 expression was significantly increased in IPF lung tissue 
homogenates on the mRNA as well as on the protein level. The enhanced expression of 
the DKK proteins underlines an aberrant WNT/β-catenin pathway activation in IPF, as 
they are known target genes of this signal transduction cascade 
10,53,122,130
. However, this 
established negative-feedback-loop does not seem to be sufficient to effectively inhibit 
the abnormal activation of WNT/β-catenin signaling in IPF. Since DKK proteins and 
their receptors are mainly expressed in the lung epithelium, the homogenate derived 
data are subject to the cellular composition of the samples. As a next step, the results of 
the present study should be supplemented by expression analyses on isolated pulmonary 
epithelial cells. 
The lung epithelium is of essential interest for the pathogenesis and disease progression 
in IPF 
25,143,160
 and it seems to be the center of DKK induced WNT modulation, as it 
expresses DKK ligands and receptors. Therefore, autocrine and paracrine effects appear 
to be the major type of DKK interference with WNT in the lung. 
The distinct accumulation of DKK1 in basal bronchial epithelial cells and its influence 
on bronchial epithelial cell proliferation 
131
 underline this protein as an interesting re-
search target concerning the maintenance and repair of the bronchial epithelium. Future 
experiments should focus on DKK1 influence in IPF, where aberrantly activated 
WNT/β-catenin signaling is present at proliferative lesions of atypical basal airway 
cells 
26
. Moreover, the influence of DKK1 on formation and growth of squamous dys-
plasia and squamous cell carcinoma of the lung should be addressed. Future in vitro 
studies should focus on primary basal cells of the bronchial epithelium to elucidate the 
effects of DKK1 on bronchial epithelial cell proliferation. 
Therapeutic antifibrotic capabilities of DKK1 via inhibition of WNT have already been 
stated in animal models of cholestatic liver fibrosis 
23
 and renal fibrosis 
62
. Furthermore, 
the inhibition of WNT target gene transcription was able to suppress lung fibrosis in the 
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bleomycin mouse model 
63,82,183
. Future in vivo studies about DKK1 in mice with 
bleomycin induced pulmonary fibrosis could possibly reveal whether this protein pos-
sesses therapeutic capabilities for IPF, while limitations of this animal model concern-
ing the transferability to some aspects of IPF pathobiology 
113
 will have to be taken into 
account. 
 
57 
5. Summary 
5 Summary 
Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease that causes de-
struction of the lungs’ architecture by accumulation of scar tissue. The prognosis of IPF 
is poor and currently the benefit of pharmaceutical treatment is very limited. The 
pathogenetic mechanisms underlying initiation and progression of the disease are still 
not completely elucidated and are subject of current investigations. 
An aberrant activation of the WNT/β-catenin signaling pathway in the lung tissue of IPF 
patients has recently been reported and an inhibition of this signal transduction cascade 
was demonstrated to be able to attenuate bleomycin induced pulmonary fibrosis in mice. 
The present study focused on Dickkopf (DKK) proteins, potent modulators of the 
WNT/β-catenin pathway. An antifibrotic effect of these proteins via inhibition of 
WNT/β-catenin signaling has already been demonstrated in mouse models of other fi-
brosing diseases. However, the role of DKK proteins in IPF had not been addressed 
before. Therefore the aim of the present study was to investigate and to compare the 
expression and localization of DKK proteins and their receptors low density lipoprotein 
receptor-related protein (LRP) and Kremen (KRM) in the unaffected adult human lung 
and in IPF. 
By quantitative reverse transcription polymerase chain reaction (qRT-PCR) and West-
ern blot analysis, DKK proteins as well as their LRP and KRM receptors were found 
expressed in unaffected donor and in IPF lung tissues, with a significantly enhanced 
expression of DKK1, DKK4 and KRM1 in the fibrotic lungs. 
Immunohistochemistry identified the bronchial epithelium of donors and IPF patients as 
well as hyperplastic alveolar epithelial cells of IPF patients as major sources for DKK 
proteins and their receptors in the lung tissue. A pronounced and distinct accumulation 
of DKK1 was observed in basal bronchial epithelial cells, one of the cell populations 
considered as epithelial progenitors. 
Additionally, an enhanced DKK1 protein content was detected in bronchoalveolar lav-
age fluids of IPF patients by an enzyme-linked immunosorbent assay (ELISA). 
Analysis of the human bronchial epithelial cell line BEAS-2B by qRT-PCR demonstrat-
ed that besides the DKK receptors, other key components of the WNT/β-catenin signal-
ing cascade can be expressed by human bronchial epithelial cells as well. 
Taken together, these data indicate an autocrine or paracrine mode of action for DKK at 
the bronchial epithelium. 
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In summary, DKK proteins and their receptors are largely located in the lung epithelium 
and their expression is altered in IPF. Since an impairment of epithelial functions is a 
key feature of IPF, DKK proteins may be of interest for the understanding of IPF patho-
genesis and for treatment strategies of this fatal lung disease. 
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6 Zusammenfassung 
Die idiopathische Lungenfibrose (IPF) ist eine schwerwiegende interstitielle Lungener-
krankung, bei welcher durch Anhäufung von Narbengewebe die Lungenarchitektur zer-
stört wird. Die IPF hat eine schlechte Prognose und derzeit ist der Nutzen von medika-
mentösen Behandlungen sehr begrenzt. Die Pathomechanismen, welche dem Beginn 
sowie dem Fortschreiten der Erkrankung zugrunde liegen, sind immer noch nicht voll-
ständig aufgeklärt und sind Gegenstand der aktuellen Forschung. 
Es wurde bereits über eine abnorme Aktivierung des WNT/β-catenin-Signalwegs im 
Lungengewebe von IPF Patienten berichtet und es konnte gezeigt werden, dass die Un-
terbindung dieser Signaltransduktionskaskade die Bleomycin-induzierte Lungenfibrose 
in Mäusen hemmt. 
Die vorliegende Arbeit hat die Dickkopf (DKK) Proteine betrachtet, bei welchen es sich 
um potente Modulatoren des WNT/β-catenin-Signalwegs handelt. Ein antifibrotischer 
Effekt dieser Proteine mittels Hemmung der WNT/β-catenin-Signaltransduktion konnte 
bereits in Maus-Modellen anderer fibrosierender Erkrankungen gezeigt werden. Die 
Rolle von DKK Proteinen in der IPF war zuvor jedoch noch nicht untersucht worden. 
Ziel der gegenwärtigen Studie war es daher, die Expression und Lokalisation von DKK 
Proteinen und deren Rezeptoren Low Density Lipoprotein Receptor-related Protein 
(LRP) und Kremen (KRM) in der nicht betroffenen Erwachsenenlunge und in der IPF 
Lunge zu untersuchen und zu vergleichen. 
Mittels quantitativer Real Time Polymerase-Kettenreaktion (qRT-PCR) und Western 
Blot Analyse konnte die Expression von DKK Proteinen und deren Rezeptoren im 
Lungengewebe von nicht betroffenen Spendern und IPF Patienten aufgezeigt werden, 
wobei DKK1, DKK4 und KRM1 in den fibrotischen Lungen signifikant verstärkt 
exprimiert wurden. 
Immunhistochemische Untersuchungen identifizierten das Bronchialepithel von Spen-
dern und IPF Patienten sowie hyperplastische Alveolarepithelzellen von IPF Patienten 
als Hauptquellen von DKK Proteinen und deren Rezeptoren im Lungengewebe. Es 
wurde eine deutlich verstärkte Anhäufung von DKK1 in basalen Bronchialepithelzellen 
beobachtet, eine der Zellpopulationen welche als epitheliale Vorläuferzellen angesehen 
werden. 
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Außerdem wurde mittels eines enzymgekoppelten Immunadsorptionstests (ELISA) ein 
erhöhter Gehalt an DKK1 Protein in bronchoalveolären Lavageflüssigkeiten von IPF 
Patienten festgestellt. 
Die Untersuchung der humanen Bronchialepithelzelllinie BEAS-2B mittels qRT-PCR 
zeigte, dass außer den DKK-Rezeptoren auch weitere Schlüssel-Moleküle des WNT/β-
catenin Signalwegs von humanen Bronchialepithelzellen exprimiert werden können. 
In der Zusammenschau weisen diese Erkenntnisse auf eine autokrine oder parakrine 
Wirkungsweise von DKK am Bronchialepithel hin. 
Zusammengefasst zeigen die Ergebnisse der vorliegenden Arbeit, dass DKK Proteine 
und deren Rezeptoren überwiegend im Lungenepithel vorkommen und dass ihre Ex-
pression in der IPF verändert ist. Da die Beeinträchtigung von epithelialen Funktionen 
ein Schlüsselmerkmal der IPF ist, könnten DKK Proteine für das Verständnis der IPF-
Pathogenese und für Behandlungsstrategien dieser schwerwiegenden Lungenerkran-
kung von Interesse sein. 
 
61 
7. Abbreviations 
7 Abbreviations 
A     ampere 
AEC    alveolar epithelial cells 
AIP    acute interstitial pneumonia 
APC    adenomatous polyposis coli 
APS    ammonium persulfate 
ALAT    Latin American Thoracic Association 
ATI cells   alveolar epithelial type I cells 
ATII cells   alveolar epithelial type II cells 
ATS    American Thoracic Society 
BAL    bronchoalveolar lavage 
BALF    bronchoalveolar lavage fluid 
bp     base pair 
BSA    bovine serum albumin 
C     cytosine 
°C     degree Celsius 
Ca
2+
    calcium 
cDNA    complementary deoxyribonucleic acid 
CK     casein kinase 
CO     carbon monoxide 
CO2    carbon dioxide 
COP    cryptogenic organizing pneumonia 
Ct     threshold cycle 
     delta 
dd     double distilled 
DIP    desquamative interstitial pneumonia 
DKK    Dickkopf 
DLCO    diffusing capacity of the lung for CO 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleoside triphosphate 
DPLD    diffuse parenchymal lung disease 
DSH    Dishevelled 
DTT    dithiothreitol 
EDTA    ethylenediaminetetraacetic acid 
EGTA    ethylene glycol tetraacetic acid 
ELISA    enzyme-linked immunosorbent assay 
EMT    epithelial-mesenchymal transition 
ERS    European Respiratory Society 
FEV1     forced expiratory volume in 1 second 
for     forward 
FVC    forced vital capacity 
FZD    Frizzled 
g     gram 
G     guanine 
GSK    glycogen synthase kinase 
h     hour 
H2O2    hydrogen peroxide 
HEPES   2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HPRT    hypoxanthine-guanine phosphoribosyltransferase 
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HRCT    high-resolution computed tomography 
HRP    horseradish peroxidase 
IgG    immunoglobulin G 
IGFBP    insulin-like growth factor-binding protein 
IHC    immunohistochemistry 
IIP     idiopathic interstitial pneumonia 
ILD    interstitial lung disease 
IPF    idiopathic pulmonary fibrosis 
JNK    c-Jun N-terminal kinase 
JRS    Japanese Respiratory Society 
kDA    kilo (10
3
) Dalton 
KRM    Kremen 
l     liter 
LEF    lymphoid enhancer-binding factor 
LIP    lymphoid interstitial pneumonia 
LRP    low density lipoprotein receptor-related protein 
m     milli (10
-3
) 
mm    millimeter 
M     mol/l 
µ     micro (10
-6
) 
MgCl2    magnesium chloride 
mmHg    millimeter of mercury 
min    minutes 
MMP    matrix metalloproteinase 
mRNA    messenger RNA 
MuLV    murine leukemia virus 
n     nano (10
-9
) 
n/a     not available 
NaCl    sodium chloride 
NCBI    National Center for Biotechnology Information 
no.     number 
NSCLC   non-small-cell lung carcinoma 
NSIP    nonspecific interstitial pneumonia 
O2     (di)oxygen 
OD    optical density 
p     pico (10
-12
) 
PaO2 / PaCO2  partial pressure of O2 / CO2 in the arterialized ear lobe blood sample  
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
q     quantitative 
qRT-PCR   quantitative reverse transcription PCR 
RB-ILD   respiratory bronchiolitis-associated interstitial lung disease 
rev     reverse 
RNA    ribonucleic acid 
rpm    rounds per minute 
RT     reverse transcription / reverse transcriptase 
s     seconds 
SCC    squamous cell carcinoma 
SDS    sodium dodecyl sulfate 
SDS-PAGE  SDS polyacrylamide gel electrophoresis 
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SEM    standard error of the mean 
SFRP    secreted frizzled-related protein 
stdev    standard deviation 
TAE    Tris, acetic acid and EDTA 
TCF    T-cell-specific transcription factor 
TGF    transforming growth factor 
TEMED   tetramethylethylenediamine 
TLC    total lung capacity 
Tris    trishydroxymethylaminomethane 
U     enzyme unit 
UDG    uracil-DNA glycosylase 
UIP    usual interstitial pneumonia 
UV    ultraviolet 
V     volt 
VA    alveolar volume 
VC     vital capacity 
v/v     volume fraction 
WB    Western blot 
WIF    WNT inhibitory factor 
WISP    WNT1-inducible-signaling pathway protein 
w/v    mass concentration (mass / volume percentage) 
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10.1 Table 1  Lung tissue biopsies 
Characteristics of IPF patients. 
VC = vital capacity, TLC = total lung capacity, DLCO/VA = diffusing capacity of the 
lung for CO per unit of alveolar volume (all in % predicted), O2 = additional nasal oxy-
gen supplementation during blood gas analysis, PaO2 / PaCO2 = partial pressure of O2 / 
CO2 in the arterialized ear lobe blood sample, n/a = not available. 
 
no. diagnosis gender age 
(years) 
VC 
(%) 
TLC 
(%) 
DLCO/VA 
(%) 
O2 
(l/min) 
PaO2 
(mmHg) 
PaCO2 
(mmHg) 
1 IPF/UIP male 63 56 48 33 3 52 33 
2 IPF/UIP male 62 50 52 26 3 49 38 
3 IPF/UIP male 58 49 n/a n/a n/a n/a n/a 
4 IPF/UIP male 65 59 42 20 3 53 38 
5 IPF/UIP male 65 59 42 20 4 69 41 
6 IPF/UIP male 43 48 51 27 n/a n/a n/a 
7 IPF/UIP male 71 40 46 24 n/a n/a n/a 
8 IPF/UIP male 64 59 52 22 2 58 38 
9 IPF/UIP male 60 51 49 18 2 59 39 
10 IPF/UIP male 65 51 66 20 2 53 38 
11 IPF/UIP male 44 47 55 25 2 36 35 
12 IPF/UIP female 43 40 n/a n/a 2 54 35 
13 IPF/UIP female 42 50 58 17 3 52 36 
14 IPF/UIP female 66 29 45 23 4 56 45 
15 IPF/UIP female 62 27 48 n/a 4 71 65 
 
10.2 Table 2  Bronchoalveolar lavage fluids (BALF) 
Characteristics of IPF patients. 
VC = vital capacity, TLC = total lung capacity, DLCO/VA = diffusing capacity of the 
lung for CO per unit of alveolar volume (all in % predicted), O2 = additional nasal oxy-
gen supplementation during blood gas analysis, PaO2 / PaCO2 = partial pressure of O2 / 
CO2 in the arterialized ear lobe blood sample, n/a = not available. 
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no. diagnosis gender age 
(years) 
VC 
(%) 
TLC 
(%) 
DLCO/VA 
(%) 
O2 
(l/min) 
PaO2 
(mmHg) 
PaCO2 
(mmHg) 
1 IPF/UIP male 66 86 78 56 2 90 41 
2 IPF/UIP male 76 41 47 73 - 79 38 
3 IPF/UIP male 68 57 55 37 - 51 34 
4 IPF/UIP male 60 33 42 n/a 5 69 41 
5 IPF/UIP male 64 69 71 54 - 70 35 
6 IPF/UIP male 79 81 75 42 - 45 37 
7 IPF/UIP male 65 60 62 48 - 61 34 
8 IPF/UIP male 65 64 58 75 - 78 35 
9 IPF/UIP male 69 36 41 n/a n/a 71 46 
 
10.3 Table 3  qRT-PCR primer 
Sequences were taken from the NCBI GenBank. All accession numbers are listed. 
 
gene accession  sequences ( 5´ → 3´ ) length amplicon 
β-CAT 
human 
NM001904 
for AAGTGGGTGGTATAGAGGCTCTTG 24bp 
77bp 
rev GATGGCAGGCTCAGTGATGTC 21bp 
DKK1 
human 
NM012242 
for CGCCGAAAACGCTGCAT 17bp 
109bp 
rev TTTCCTCAATTTCTCCTCGGAA 22bp 
DKK2 
human 
NM014421 
for TCAGGCCGCCAATCGA 16bp 
85bp 
rev GTAGGCCTGCCCCAGGTT 18bp 
DKK3 
human 
NM015881 
for GCTTCTGGACCTCATCACCTG 21bp 
119bp 
rev TCGGCTTGCACACATACACC 20bp 
DKK4 
human 
NM014420 
for GAAGGGCTCACAGTGCCTGT 20bp 
131bp 
rev AGCACATGGCATCTCGCTG 19bp 
FZD1 
human 
NM003505 
for AGCGCCGTGGAGTTCGT 17bp 
64bp 
rev CGAAAGAGAGTTGTCTAGTGAGGAAAC 27bp 
FZD2 
human 
NM001466 
for CACGCCGCGCATGTC 15bp 
63bp 
rev ACGATGAGCGTCATGAGGTATTT 23bp 
FZD3 
human 
NM017412 
for GGTGTTCCTTGGCCTGAAGA 20bp 
72bp 
rev CACAAGTCGAGGATATGGCTCAT 23bp 
FZD4 
human 
NM12193 
for GACAACTTTCACACCGCTCATC 22bp 
164bp 
rev CCTTCAGGACGGGTTCACA 19bp 
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GSK3β 
human 
NM002093 
for CTCATGCTCGGATTCAAGCA 20bp 
86bp 
rev GGTCTGTCCACGGTCTCCAGTA 22bp 
HPRT1 
human 
NM000194 
for AAGGACCCCACGAAGTGTTG 20bp 
157bp 
rev GGCTTTGTATTTTGCTTTTCCA  22bp 
KRM1 
human 
NM001039570 
for TGGAAGCCACAGAGTTGAAGG 21bp 
146bp 
rev GACAATCCCTAAGGTCCCCTG 21bp 
KRM2 
human 
NM172229 
for CTGGCGCTACTGCGACATC 19bp 
62bp 
rev AGTCCACAAAGCATCCCAGGTA 22bp 
LEF1 
human 
NM016269 
for CATCAGGTACAGGTCCAAGAATGA 24bp 
93bp 
rev GTCGCTGCCTTGGCTTTG 18bp 
LRP5 
human 
NM002335 
for GACCCAGCCCTTTGTTTTGAC 21bp 
134bp 
rev TGTGGACGTTGATGGTATTGGT 22bp 
LRP6 
human 
NM002336 
for GATTCAGATCTCCGGCGAATT 21bp 
83bp 
rev GGCTGCAAGATATTGGAGTCTTCT 24bp 
TCF3 
human 
NM031283 
for ACCATCTCCAGCACACTTGTCTAATA 26bp 
71bp 
rev GAGTCAGCGGATGCATGTGA 20bp 
TCF4 
human 
NM030756 
for GCGCGGGATAACTATGGAAAG 21bp 
89bp 
rev GGATTTAGGAAACATTCGCTGTGT 24bp 
WNT1 
human 
NM005430 
for CTCATGAACCTTCACAACAACGA 23bp 
80bp 
rev ATCCCGTGGCACTTGCA 17bp 
WNT3a 
human 
NM033131 
for GCCCCACTCGGATACTTCTTACT 23bp 
98bp 
rev GAGGAATACTGTGGCCCAACA 21bp 
WNT7b 
human 
NM058238 
for GCAAGTGGATTTTCTACGTGTTTCT 25bp 
65bp 
rev TGACAGTGCTCCGAGCTTCA 20bp 
WNT10b 
human 
NM003394 
for GCGCCAGGTGGTAACTGAA 19bp 
59bp 
rev TGCCTGATGTGCCATGACA 19bp 
 
10.4 Immunohistochemistry - supplements 
Immunohistochemical stainings of tissue sections from further donor and IPF lungs are 
presented on the following pages. Representative bronchial and alveolar regions of 
lungs other than depicted in the results chapter (chapter 3.2) are shown for each anti-
body. 
 
78 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
5
. 
 
L
o
ca
li
za
ti
o
n
 o
f 
D
K
K
1
 p
ro
te
in
 i
n
 d
o
n
o
r 
a
n
d
 I
P
F
 l
u
n
g
 t
is
su
e
. 
Im
m
u
n
o
h
is
to
ch
em
ic
al
 s
ta
in
in
g
 f
o
r 
D
K
K
1
 p
ro
te
in
 w
as
 p
er
fo
rm
ed
 o
n
 l
u
n
g
 t
is
su
e 
se
ct
io
n
s 
o
f 
d
o
n
o
rs
 a
n
d
 I
P
F
 p
at
ie
n
ts
. 
S
ta
in
in
g
s 
w
er
e 
p
er
fo
rm
ed
 a
t 
le
as
t 
tw
ic
e 
u
si
n
g
 t
h
re
e 
d
if
fe
re
n
t 
d
o
n
o
r 
an
d
 I
P
F
 l
u
n
g
 t
is
su
es
. 
R
ep
re
se
n
ta
ti
v
e 
b
ro
n
ch
ia
l 
(A
) 
an
d
 
a
lv
eo
la
r
 (
B
) 
re
g
io
n
s 
o
f 
d
o
n
o
r 
(l
ef
t 
p
a
n
el
s)
 a
n
d
 I
P
F
 (
ri
g
h
t 
p
a
n
el
s)
 l
u
n
g
s 
ar
e 
sh
o
w
n
 i
n
 t
h
re
e 
m
ag
n
if
ic
at
io
n
s 
as
 i
n
d
ic
at
ed
. 
B
. 
A
. 
79 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
6
. 
 
L
o
ca
li
za
ti
o
n
 o
f 
D
K
K
4
 p
ro
te
in
 i
n
 d
o
n
o
r 
a
n
d
 I
P
F
 l
u
n
g
 t
is
su
e
. 
Im
m
u
n
o
h
is
to
ch
em
ic
al
 s
ta
in
in
g
 f
o
r 
D
K
K
4
 p
ro
te
in
 w
as
 p
er
fo
rm
ed
 o
n
 l
u
n
g
 t
is
su
e 
se
ct
io
n
s 
o
f 
d
o
n
o
rs
 a
n
d
 I
P
F
 p
at
ie
n
ts
. 
S
ta
in
in
g
s 
w
er
e 
p
er
fo
rm
ed
 a
t 
le
as
t 
tw
ic
e 
u
si
n
g
 t
h
re
e 
d
if
fe
re
n
t 
d
o
n
o
r 
an
d
 I
P
F
 l
u
n
g
 t
is
su
es
. 
R
ep
re
se
n
ta
ti
v
e 
b
ro
n
ch
ia
l 
(A
) 
an
d
 
a
lv
eo
la
r
 (
B
) 
re
g
io
n
s 
o
f 
d
o
n
o
r 
(l
ef
t 
p
a
n
el
s)
 a
n
d
 I
P
F
 (
ri
g
h
t 
p
a
n
el
s)
 l
u
n
g
s 
ar
e 
sh
o
w
n
 i
n
 t
h
re
e 
m
ag
n
if
ic
at
io
n
s 
as
 i
n
d
ic
at
ed
. 
B
. 
A
. 
80 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
7
. 
 
L
o
ca
li
za
ti
o
n
 o
f 
L
R
P
5
 p
ro
te
in
 i
n
 d
o
n
o
r 
a
n
d
 I
P
F
 l
u
n
g
 t
is
su
e
. 
Im
m
u
n
o
h
is
to
ch
em
ic
al
 s
ta
in
in
g
 f
o
r 
L
R
P
5
 p
ro
te
in
 w
as
 p
er
fo
rm
ed
 o
n
 l
u
n
g
 t
is
su
e 
se
ct
io
n
s 
o
f 
d
o
n
o
rs
 a
n
d
 I
P
F
 p
at
ie
n
ts
. 
S
ta
in
in
g
s 
w
er
e 
p
er
fo
rm
ed
 a
t 
le
as
t 
tw
ic
e 
u
si
n
g
 t
h
re
e 
d
if
fe
re
n
t 
d
o
n
o
r 
an
d
 I
P
F
 l
u
n
g
 t
is
su
es
. 
R
ep
re
se
n
ta
ti
v
e 
b
ro
n
ch
ia
l 
(A
) 
an
d
 
a
lv
eo
la
r
 (
B
) 
re
g
io
n
s 
o
f 
d
o
n
o
r 
(l
ef
t 
p
a
n
el
s)
 a
n
d
 I
P
F
 (
ri
g
h
t 
p
a
n
el
s)
 l
u
n
g
s 
ar
e 
sh
o
w
n
 i
n
 t
h
re
e 
m
ag
n
if
ic
at
io
n
s 
as
 i
n
d
ic
at
ed
. 
B
. 
A
. 
81 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
8
. 
 
L
o
ca
li
za
ti
o
n
 o
f 
K
R
M
1
 p
ro
te
in
 i
n
 d
o
n
o
r 
a
n
d
 I
P
F
 l
u
n
g
 t
is
su
e
. 
Im
m
u
n
o
h
is
to
ch
em
ic
al
 s
ta
in
in
g
 f
o
r 
K
R
M
1
 p
ro
te
in
 w
as
 p
er
fo
rm
ed
 o
n
 l
u
n
g
 t
is
su
e 
se
ct
io
n
s 
o
f 
d
o
n
o
rs
 a
n
d
 I
P
F
 p
at
ie
n
ts
. 
S
ta
in
in
g
s 
w
er
e 
p
er
fo
rm
ed
 a
t 
le
as
t 
tw
ic
e 
u
si
n
g
 t
h
re
e 
d
if
fe
re
n
t 
d
o
n
o
r 
an
d
 I
P
F
 l
u
n
g
 t
is
su
es
. 
R
ep
re
se
n
ta
ti
v
e 
b
ro
n
ch
ia
l 
(A
) 
an
d
 
a
lv
eo
la
r
 (
B
) 
re
g
io
n
s 
o
f 
d
o
n
o
r 
(l
ef
t 
p
a
n
el
s)
 a
n
d
 I
P
F
 (
ri
g
h
t 
p
a
n
el
s)
 l
u
n
g
s 
ar
e 
sh
o
w
n
 i
n
 t
h
re
e 
m
ag
n
if
ic
at
io
n
s 
as
 i
n
d
ic
at
ed
. 
B
. 
A
. 
82 
10. Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 1
9
. 
 
L
o
ca
li
za
ti
o
n
 o
f 
K
R
M
2
 p
ro
te
in
 i
n
 d
o
n
o
r 
a
n
d
 I
P
F
 l
u
n
g
 t
is
su
e
. 
Im
m
u
n
o
h
is
to
ch
em
ic
al
 s
ta
in
in
g
 f
o
r 
K
R
M
2
 p
ro
te
in
 w
as
 p
er
fo
rm
ed
 o
n
 l
u
n
g
 t
is
su
e 
se
ct
io
n
s 
o
f 
d
o
n
o
rs
 a
n
d
 I
P
F
 p
at
ie
n
ts
. 
S
ta
in
in
g
s 
w
er
e 
p
er
fo
rm
ed
 a
t 
le
as
t 
tw
ic
e 
u
si
n
g
 t
h
re
e 
d
if
fe
re
n
t 
d
o
n
o
r 
an
d
 I
P
F
 l
u
n
g
 t
is
su
es
. 
R
ep
re
se
n
ta
ti
v
e 
b
ro
n
ch
ia
l 
(A
) 
an
d
 
a
lv
eo
la
r
 (
B
) 
re
g
io
n
s 
o
f 
d
o
n
o
r 
(l
ef
t 
p
a
n
el
s)
 a
n
d
 I
P
F
 (
ri
g
h
t 
p
a
n
el
s)
 l
u
n
g
s 
ar
e 
sh
o
w
n
 i
n
 t
h
re
e 
m
ag
n
if
ic
at
io
n
s 
as
 i
n
d
ic
at
ed
. 
B
. 
A
. 
  83 
11. Publications and Presentations  
11 Publications and presentations 
11.1 Publications 
1. Pfaff EM, Becker S, Gunther A, et al: Dickkopf proteins influence lung epithelial 
 cell proliferation in idiopathic pulmonary fibrosis. Eur Respir J 37:79-87, 2011 
 
2.  Konigshoff M, Balsara N, Pfaff EM, et al: Functional Wnt signaling is increased in 
idiopathic pulmonary fibrosis. PLoS One 3:e2142, 2008 
 
11.2 Oral presentation 
Freier Vortrag, Sektion Zellbiologie, 49. Kongress der Deutschen Gesellschaft für 
Pneumologie und Beatmungsmedizin e.V., Lübeck, April 2008. E. Pfaff/Gießen, N. 
Balsara, O. Eickelberg, M. Königshoff. Expression und Lokalisation von Wnt-
Inhibitoren in der idiopathischen Lungenfibrose. 
 
84 
12. Erklärung zur Dissertation 
12 Erklärung zur Dissertation 
„Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig und ohne unzulässige 
Hilfe oder Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Alle 
Textstellen, die wörtlich oder sinngemäß aus veröffentlichten oder nichtveröffentlichten 
Schriften entnommen sind, und alle Angaben, die auf mündlichen Auskünften beruhen, 
sind als solche kenntlich gemacht.  Bei den von mir durchgeführten und in der Disserta-
tion erwähnten Untersuchungen habe ich die Grundsätze guter wissenschaftlicher Pra-
xis, wie sie in der „Satzung der Justus-Liebig-Universität Gießen zur Sicherung guter 
wissenschaftlicher Praxis“ niedergelegt sind, eingehalten sowie ethische, datenschutz-
rechtliche und tierschutzrechtliche Grundsätze befolgt. Ich versichere, dass Dritte von 
mir weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten haben, 
die im Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen, oder habe 
diese nachstehend spezifiziert. Die vorgelegte Arbeit wurde weder im Inland noch im 
Ausland in gleicher oder ähnlicher Form einer anderen Prüfungsbehörde zum Zweck 
einer Promotion oder eines anderen Prüfungsverfahrens vorgelegt. Alles aus anderen 
Quellen und von anderen Personen übernommene Material, das in der Arbeit verwendet 
wurde oder auf das direkt Bezug genommen wird, wurde als solches kenntlich gemacht. 
Insbesondere wurden alle Personen genannt, die direkt und indirekt an der Entstehung 
der vorliegenden Arbeit beteiligt waren. Mit der Überprüfung meiner Arbeit durch eine 
Plagiatserkennungssoftware bzw. ein internetbasiertes Softwareprogramm erkläre ich 
mich einverstanden.“ 
 
 
______________________         _______________________ 
Ort, Datum             Unterschrift 
 
85 
14. Curriculum vitae 
13 Danksagung 
Besonders bedanken möchte ich mich bei Dr. Dr. Melanie Königshoff für die Betreuung 
während der Zeit in der ehemaligen Arbeitsgruppe und auch bei der nachfolgenden 
Ausarbeitung. Ich bin ihr sehr dankbar für die Unterstützung in den vielen theoretischen 
und praktischen Fragen sowie für ihre Begeisterungsfähigkeit, womit sie mich immer 
wieder motiviert hat. 
 
Besonderer Dank geht auch an Prof. Dr. Oliver Eickelberg. Er hat mir ermöglicht, in 
einer engagierten Arbeitsgruppe das wissenschaftliche Arbeiten zu erlernen. Ich danke 
ihm für das Schaffen eines besonders angenehmen und motivierenden Arbeitsumfeldes 
mit vielen Möglichkeiten zur produktiven Diskussion. 
 
Bei Simone Becker möchte ich mich herzlich für die geduldige Unterstützung bei den 
praktischen Schwierigkeiten und ihre stete Hilfsbereitschaft bedanken. 
 
Anna Lühring, Nisha Balsara und Monika Kramer danke ich für freundliche Worte an 
anstrengenden Tagen und fürs Zuhören. 
 
Der gesamten ehemaligen Arbeitsgruppe gilt ein großer Dank für ihre Hilfsbereitschaft, 
für anregende Diskussionen und für das freundliche Miteinander. 
